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LARGE-SCALE SINGLE-CELL TRANSCRIPTOMICS OF OSTEOSARCOMA 
 
REVEALS EXTENSIVE AND DIFFERENT HETEROGENEITY IN PRIMARY 
 
TUMORS VERUS MURINE XENOGRAFT MODEL 
STEFAN HALVORSEN 
ABSTRACT 
Heterogeneity within tumors has long been studied as a potential confounding factor for 
effective therapies, with recent studies pointing to heterogeneity resulting in distinct 
clonal subtypes, each with varying degrees of fitness and metastatic potential. Studies of 
heterogeneity have previously been limited to microscopy observations, 
immunohistochemistry, and flow cytometry. Recently, however, it has become possible 
to examine heterogeneity at a previously unexplored level: the transcriptome of 
individual cells. 
Osteosarcomas have been known to be highly heterogeneous, so we have selected 
osteosarcoma as our primary tumor to study as a proof-of-concept. Additionally, we have 
elected to create a murine patient derived xenograft (PDX) model from a primary 
osteosarcoma tumor and examine differences between the primary tumor and resulting 
xenograft at the single-cell level. Through this, we hope to better understand tumor 
heterogeneity and add to the current discussion in the scientific community regarding the 
relevance of PDX models for testing promising new therapies and personalized medicine. 
Through our examination of single-cell heterogeneity in osteosarcomas, we have 
confirmed the extensive heterogeneity previously reported, but this time at the level of 
mRNA. The osteosarcomas were so hetereogeneous that our resulting dataset of over 
		 vi 
1,000 cells still did not have enough resolution to generate highly differentiated and 
separate groupings of cells. Upon examining inter-tumor heterogeneity, we observed the 
cells from different tumors to generally cluster separately. However, there were certain 
populations of cells from all tumors that clustered together. We also generated a PDX 
model and sequenced the resulting tumor, observing markedly reduced heterogeneity as 
compared to the original primary tumor. Importantly, the cells from the PDX model 
clustered within the larger group of cells from the original tumor, lending credence to the 
theory of clonal selection. 
This work presents evidence of extensive intra- and inter-tumor heterogeneity at 
the mRNA level within osteosarcoma tumors. This heterogeneity requires further single 
cell sampling to shed light on the biology of tumor diversity. Further, this heterogeneity 
is significantly reduced in a generated murine PDX model. This difference should serve 
as a potential warning about additional factors to take into account when evaluating 
therapies in PDX models, and suggests that further studies examining cause and effect of 
this observed heterogeneity are warranted. 
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INTRODUCTION 
To date, much of the science centered on tumor biology has analyzed the tumor as a 
whole. However, it has always been known that there is significant intra-tumor 
heterogeneity. The problem was, until recently, no viable technology was available for 
exploring the extent of the heterogeneity contained in a tumor or any complex tissue. 
With the recent proliferation of single-cell analyses, it has finally become feasible to 
explore the heterogeneity of tissues on a mass scale. 
 
The Importance of Single-Cell Analysis 
Recent studies in tumor heterogeneity have only just started to explore the extent of 
variation among cells in common tumors, such as breast cancer and glioblastoma 1 2 3 4 5 
6. These studies have shown that single cells vary significantly from the average, which 
represents the only available snapshot of tumors when traditional bulk tissue analyses are 
performed. These differences can yield important clinical ramifications, and could 
potentially provide insight into the cause of clinical recurrence and resistance to 
treatments. Moreover, these recent studies have shown that the clinical subtype 
classification for some tumors can be wildly inaccurate, as the individual cells exhibit 
extensive coverage of many different subtypes compared to the bulk tumor analysis 3. 
In addition to exposing tumor heterogeneity, single cell analysis has the 
unprecedented ability to study extremely rare cell populations, such as circulating tumor 
cells (CTCs). CTCs are exceedingly rare (on the order of one in a billion blood cells), and 
thus the isolation and enrichment of these cells proves very difficult. Even in a highly 
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enriched sample of CTCs, there will still be abundant contamination from white blood 
cells (WBC) 7. As such, the sample needs to be analyzed on a single-cell level in order to 
elucidate a signal of interest as coming from a CTC as opposed to a WBC. Single-cell 
studies on CTCs have the potential to elicit an enormous impact on clinical therapies and 
prognosis metrics, as CTCs have been hypothesized to play a significant role in cancer 
metastasis 8 4. 
 
Heterogeneity in Sarcomas 
Sarcomas have long been known to exhibit extensive heterogeneity. Some of the earliest 
reported work describing sarcoma heterogeneity documented phenotypic diversity in 
metastatic potential arising within a mouse KHT sarcoma line 9. Following this, cellular 
morphological diversity has been reported arising from a single specimen of human 
sarcoma 10 as well as macro-scale morphological heterogeneity 11. Further research has 
shown significant heterogeneity among the sarcoma cell line GRU-1, which was derived 
from a single clonogenic tumor cell, and indicates innate potential for heterogeneity 
among at least a subset of sarcoma cells 12. Aside from mouse studies, there have been 
efforts to examine the heterogeneity present in histological structure as well as 
antibodies, protein biomarkers, and DNA ploidy/content in a tumor bank of paraffin-
embedded Ewing’s sarcoma samples 13 14 15. 
 
Clinical Implications of Heterogeneity 
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Heterogeneity among tumors is an established fact, but the impact this has on clinical 
practice has yet to be fully explored. The impact of this heterogeneity is potentially very 
significant, and there has been a conscious effort to tease out the effects in recent years. 
Early research on the GRU-1 sarcoma cell line and its’ subclones (all of these originated 
from one single cell) has shown a highly differential response to the chemotherapy drug 
Paclitaxel 16. A more general approach has also shown a clinically significant inverse 
correlation between sarcoma heterogeneity, as indicated by PET, and patient survival, 
although the reasons for this have not been concretely established 17. Some theories about 
the importance of heterogeneity in clinical prognosis have honed in on one subgroup of 
cells present in a tumor, namely the cancer stem-like cells (CSCs), which has the 
capability to add plasticity and increase the likelihood of recurrence. Some studies have 
demonstrated markedly decreased tumorigenic proliferation in xenograft models by 
specifically targeting CSCs in addition to the tumor bulk 18. 
 
Clinical Implications of Single-Cell Analysis 
The aspects in which single cell analysis has the power to change the way we practice 
medicine are widespread and not yet fully developed, however some of the obvious 
applications for single cell analysis include:  
• Generating biomarkers for CTCs and CSCs to be used in targeted therapy 18 19 
7 4 20 5 2 
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• Taking the current standards of personalized medicine one step further by 
identifying and classifying additional subtypes of cancer and corresponding 
treatments 6 3 19 1 
• Clinical tests to determine likely prognosis and potential paths for treatment 
based on level of heterogeneity as well as CTC level and types 19 21 4  
With new methods enabling single cell analysis on a mass scale never before possible, we 
can no longer ignore the effects of tumor heterogeneity on clinical prognosis and 
treatment. 
 
Principles of Droplet Microfluidics 
Droplet microfluidics utilize a specific design of tubing and flow junctions to produce a 
stable oil-aqueous emulsion of droplets on the nano-liter scale. For many biological 
analyses, an organic continuous phase is utilized, and the droplets are used as aqueous 
phase micro-reactors. In order to stabilize the droplets and prevent coalescence (multiple 
droplets merging into one), a surfactant is generally added to the oil phase which lowers 
the interfacial tension 22 23. In many biological applications, fluorinated oil is often used 
instead of a standard hexadecane or mineral oil. The fluorinated oil has a lower tendency 
to swell the PDMS material that many microfluidic devices are currently fabricated from, 
and fluorinated oil tends to be more permeable to gas and vapor than other oils. This 
increased permeability can be disadvantageous for cross-contamination issues, but is 
necessary to provide an oxygen supply to cells encased within a droplet when further 
culture within the droplets is required 23. 
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An important part of a droplet generation device is the junction where the 
dispersed liquid is pinched off into droplets by the continuous phase. Two of the more 
common styles of junctions are illustrated in Fig. 1 23. 
 
Fig. 1: An illustration of a droplet getting pinched off in a (A) flow-focusing type 
junction or (B) T-junction 23 
 
Droplet Microfluidics Applied to Single-Cell Analysis 
Single-cell analysis has been one obvious application of droplet microfluidics from the 
early days of the field, gaining popularity around the year 2000. There have been, 
however, several barriers to overcome before successful single-cell analyses could 
become commonplace. One of the major technical hurdles is to ensure that only one 
single cell has been encapsulated in every droplet. Cell loading into droplets typically 
follows a Poisson distribution, so in order to minimize the possibility of multiple cells 
ending up in a single droplet, the cell loading density has to be low, to the point where the 
majority of droplets are empty. One approach to dealing with this hurdle has been to 
increase the throughput in order to collect sufficient data from the rare occupied droplets. 
A B
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This necessitates increased time and reagent cost, and, in some cases, precludes the 
possibility of working with rare cell populations 24. 
An alternate approach could involve using a low cell loading density and 
enriching the droplet pool for droplets that captured a cell. This could be done by tagging 
the cells with a fluorescent marker and sorting the droplets via FACS, or by setting up a 
laser fluorescence detection system coupled with an automatic switching circuit that 
diverts the occupied droplets to a different output by exploiting the dielectrophoretic 
effect 23. The enriched pool of droplets could then be utilized in further downstream 
analysis, such as injection of PCR reagents and thermocycling. This approach presents a 
greatly increased barrier to system setup, owing to increased cost, calibration, and time 
needed. Further, these techniques require technical skills that are uncommon in biological 
research. 
A more feasible approach to maximizing the number of droplets containing one 
single cell is to load a high-density cell suspension into a high aspect-ratio microchannel, 
causing the cells to form a highly regular flow 25. This is a technique that holds 
tremendous promise, but has not yet been applied to the latest advancements in single-
cell assays, with the majority of recent publications utilizing the standard Poisson 
distribution for cell encapsulation 26 24. 
Yet another obstacle has been labeling the droplets for downstream analysis. In 
the case of optical assays, such as qPCR or fluorescence detection, the entire process is 
done within droplets and no molecular labeling is necessary. However, for processes 
which require downstream manipulation, such as sequencing, it is necessary to label each 
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droplet with a unique identifier so that it becomes possible to identify data associated 
with different droplets, and, thus, separate cells. The latest generation of single-cell 
mRNA sequencing methods both use a unique DNA identifier that is inserted into each 
droplet in order to form a barcode 26 24. This barcode is retained with the mRNA for 
downstream library preparation and sequencing. The delivery method for these barcoding 
DNA oligos is similar, yet fundamentally different in a few important aspects.  
In the Drop-Seq method, barcoding oligos are synthesized directly onto 
hydroxylated beads originally meant for size-exclusion chromatography. A split-and-pool 
approach during the DNA oligo synthesis ensures all the beads contain only one cell 
barcode while also ensuring exclusivity for a given barcode among the entire pool of 
beads. A further 8 degenerate DNA bases are added after the cell barcode synthesis, 
which collectively form a Unique Molecular Identifier (UMI). The purpose of the UMI is 
to barcode individual transcripts, allowing for a fully digital quantification of mRNA 
expression levels. The barcoding oligo ends with a poly-T tail in order to capture mRNA 
poly-A tails 24. 
In the inDrop method, the authors also use a similar split-and-pool approach, but 
rely on two 384-well plates with unique barcodes in each well to do the pooling. As such, 
the total number of unique barcodes is much smaller. Additionally, with inDrop, the 
barcoding oligos are not attached to solid-state beads, but rather they are linked to a 
hydrogel matrix by a photo-cleavable spacer. This approach offers a few distinct 
advantages over the DropSeq method. By using a deformable material to deliver the 
barcoding oligos, the inDrop microfluidics chip can be designed in order to squeeze the 
	8 
hydrogel beads into a channel, single-file. This approach allows the inDrop method to 
surpass the Poisson statistics for droplet encapsulation and deliver one barcoding 
hydrogel bead in every single droplet. This allows every input cell to be sequenced, 
markedly increasing the efficiency as compared to DropSeq. Further, the inDrop method 
performs the reverse transcription step within the droplets, significantly reducing the 
possibility of RNA degradation that accompanies the DropSeq method 26. 
 
Patient Derived Xenograft (PDX) Murine Models 
Recently, PDX mouse models have been touted as promising and superior models to test 
cancer therapies and the future of personalized medicine. Studies have shown marked 
similarities between a PDX tumor and the original patient tumor in regards to genomics, 
metastatic potential, and response to currently known therapies 27 28 29. Although the early 
results appear promising, there has been recent concern regarding the heterogeneity of 
PDX tumors compared to the original patient tumor 30 27 29 31 32. It is entirely possible that 
the xenograft process selects for an unknown subset of cells from the original tumor 
exhibiting a higher level of fitness in the murine environment. There have been recent 
studies examining whether or not the PDX model selects for a subset of clones from the 
original tumor, and results have initially indicated that PDX tumors exhibit extensive 
heterogeneity in the clonal selection process 31. Aside from the clonal selection process, 
many of the recent studies have focused on heterogeneity in terms of stromal elements, 
with nearly all the stroma in a PDX tumor being of murine origin 30 32 27. However, we 
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are not aware of any studies that have examined the heterogeneity as a function of 
transcriptomic profiling on the single-cell level.  
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SPECIFIC AIMS 
It has recently become feasible to analyze the transcriptomes of single cells on a massive 
scale. Doing so provides a window into the heterogeneity of a cell population that we 
wish to utilize in order to examine both primary osteosarcomas and PDX tumors. 
Specifically, the goals of this thesis are: 
• Implement and improve a Drop-Seq system for single cell analysis 
• Perform single-cell RNAseq on primary osteosarcoma tumors 
• Develop PDX models from the primary tumors 
• Perform single-cell RNAseq on the PDX tumors 
• Examine the transcriptomic heterogeneity of the PDX tumors compared to the 
primary tumors 
Through the process of implementing a Drop-Seq system and analyzing the resulting 
data, it is hoped that we will generate hypotheses for future research, as well as shed 
some light onto the potential changes involved in the transformation of a primary tumor 
into a murine PDX tumor. 
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METHODS 
Tumor Collection and Single Cell Dissociation 
Fresh tumor samples were collected from the Pathology Lab at Massachusetts General 
Hospital. Only the interior of the tumor was sampled to avoid contamination from normal 
tissue, and viability and tumor identity was verified via histopathology. Disposable 
scalpels (Feather No. 21 stainless steel) were used to mince the tumor into chunks about 
8mm^3. The minced tumor was then placed in 25mL of PBS containing 0.2% 
collagenase type II (Sigma C6885), 5mM CaCl2, and 0.05 mg/mL of Gentamicin sulfate. 
This was placed in a 50mL centrifuge tube, along with a small magnetic stir bar. The tube 
was inverted and placed onto a ThermoScientific VarioMag Micro operating at 
1400RPM within a 37C incubator for 1 hour. The resulting solution was triturated with a 
25mL pipette a few times, then passed through a 60um cell-straining filter (PluriSelect 
43-50060-03), occasionally under vacuum via a connector ring (PluriSelect 41-50000-03) 
if the filter got clogged. The filter was washed with 25mL PBS. The solution was then 
centrifuged at 600g for 5 min. The supernatant was aspirated, and the resulting pellet 
resuspended in 10mL of RBC Lysis buffer (Boston BioProducts IBB-197). After 3 mins 
of incubation at room temperature, the solution was passed through a 40um cell-straining 
filter (Corning 352340), followed by 35mL PBS to stop the RBC lysis. The cells were 
then spun at 600g for 5min. If the pellet was still red, the RBC lysis procedure was 
repeated a second time. The pellet was then enriched for viable cells using OptiPrep as 
follows: cell pellet resuspended in a final volume of 540uL PBS, then supplemented with 
460uL of OptiPrep (Sigma D1556) for a final density of 1.15 g/mL. This 1mL of cell 
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suspension was added to a 15mL centrifuge tube, then 5mL of 1.12 g/mL OptiPrep 
solution (1.8mL OptiPrep with 3.2mL PBS) was slowly layered on top. As a final top 
layer, 1mL of PBS was slowly added. The volumes of these three layers were scaled as 
appropriate, but the densities of these layers were kept constant.  The resulting three 
layers were centrifuged at 800g for 20 min. The cell band containing the viable cells was 
removed from the interface between the 1.12 g/mL and PBS layers. An example of a 
successful separation, both before and after centrifugation is shown in Fig. 2. This cell 
band was washed with 40mL of PBS and centrifuged at 500g for 5 min. The supernatant 
was aspirated, and the cell pellet resuspended in 1mL of PBS. 2uL of Calcein Green 
(ThermoFisher C34852) was added and the cells were mixed then incubated at room 
temperature for 5 min. The cells were counted on a Countess II FL (ThermoFisher) using 
the Calcein as a marker for the live cells. The cells were brought to a final concentration 
of 100,000 per mL in PBS with 0.1% BSA and 10% OptiPrep (only used when running 
the beads in an OptiPrep solution). 
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Fig. 2: Viable cell isolation using OptiPrep density gradients. With an abundance of 
viable cells, one can observe the cells starting to congregate at the top of the 1.12 g/mL 
solution even before centrifugation (left), with a clear band visible after centrifugation 
(right). A high viability sample is pictured, so no pellet of dead cells is visible, although 
some debris is visible in the 1.12 g/mL layer after centrifugation. 
 
Drop-Seq System Setup 
The Microfluidic Chip 
We utilized a Dolomite microfluidics chip (Part number 3200455), fabricated from two 
layers of etched glass (Fig. 3B) as compared to the PDMS used in the original DropSeq 
method 24. The glass chip offers numerous benefits over PDMS, notably the drastically 
improved reusability. The original PDMS devices are only good for a few runs, after 
which they are tossed and a new device is used. The glass chips manufactured by 
Dolomite are usable for hundreds of runs. In addition to the reusability, the Dolomite 
1.12 g/mL
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chips are far superior in ease of use. With PDMS chips, the tubing is connected in a 
haphazard and fragile manner, with holes punched via a syringe needle and tubing 
carefully threaded in. With the Dolomite chips, the tubing is inserted into a reusable 
connector that is then clamped over the glass chips. The tubing does not need to be 
inserted carefully into the chips, and a seal is made with a rubber gasket onto the face of 
the chip (Fig. 3C). The junction design of this chip is the same as in the original Drop-
Seq paper (Fig. 3A). 
 
 
Fig. 3: (A) Diagram of the droplet forming junction, taken from the original Drop-Seq 
paper 24 (B) The Dolomite glass microfluidics chip. (C) The tubing connection clamp and 
gasket 
 
A
B C
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The Pumps 
The use of glass as the microfluidics chip material highlights the importance of a high-
quality fluid delivery system. In the original DropSeq method, fluid is delivered via 
syringe pumps. Due to the stepper motors used in these types of pumps, the fluid flow is 
necessarily pulsed, which yields lower quality droplets that can vary considerably in size 
(i.e. poor droplet monodispersity). The slightly elastic nature of the PDMS chips is able 
to somewhat offset the pulsed flow, but the stiff glass in the Dolomite chips is not. To 
alleviate this, and increase the quality of generated droplets, we purchased a set of 
pressure pumps from Dolomite. This style of pump drives fluid through the microfluidic 
system via a pressure source of up to 10 bar. In our case, we utilized a cylinder of 
compressed nitrogen with a BOG Gases regulator set to 140PSI. Another advantage of 
the pressure pumps over the syringe pumps is the ability to deliver a steady stream of 
pressurized air, which is very helpful when cleaning the reusable chips. Additionally, the 
Dolomite pressure pumps interface to their Flow Control Center software program, which 
allows for the development of custom control scripts and workflows in a language similar 
to C#. We have utilized this feature to generate a DropSeq control script that gradually 
ramps up all lines at the same time, avoiding backflow as much as possible (Appendix 
IV). 
 
The Microscope 
A way to view the flow-focusing junction on the microfluidics chip is necessary when 
performing a DropSeq run. By looking at the flow in the junction, it is possible to 
	16 
determine if droplets are being generated, and if the fluids are flowing in approximately 
the right proportions. We are using a Zeiss Axiovert 35 microscope with a 2.5X objective 
in order to view as much of the junction and surrounding channels as possible. During the 
droplet generation process, the fluids are flowing so rapidly that it is impossible to view 
individual droplets without a high-speed camera. We have attached a PixeLink PL-D725 
camera in order to analyze the droplet generation process. Limiting the region of interest 
on the camera enables us to attain frame-rates of about 3,000 frames per second. A 
sequence of frames from a high-speed video showing a bead being encapsulated is shown 
in Fig. 4. 
 
 
Fig. 4: A sequence of frames pulled from a high-speed video illustrating a bead being 
encapsulated within a droplet. Although the junction where the cells mix in with the 
beads is not visible, one can observe the two aqueous phases still distinct in the channel 
while the droplet is being formed. 
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The Beads 
In order to bypass the process of synthesizing the beads ourselves, we purchased the 
barcoded beads from ChemGenes (MACOSKO-2011-10). The first batch of beads we 
received had a faulty barcode; the 12bp cell barcode was cut short by as much as 3bp on 
some of the beads. The second batch of beads we received was improved, but a portion of 
the beads still had cell barcodes that were 1bp too short (Fig. 5). Although the cell 
barcode is cut short in a portion of the beads, the sequencing results were still usable. The 
software analysis suite developed for DropSeq includes a script to identify cases where 
the cell barcode has been cut short, and to shift all the UMIs associated with this cell 
barcode accordingly. Although we were able to deal with these imperfections in the 
barcoded beads, it highlighted a challenge in producing higher quality beads. 
 
Fig. 5: Plot showing the distribution of T nucleotides between the two batches of beads 
we received. One can observe the poly-T tail starting too early in both batches, with the 
second batch starting later than the first batch in a higher percentage of beads. 
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Keeping the beads suspended 
The base material for the beads from ChemGenes is the same as in the DropSeq paper, 
and is extremely dense. In a solution close to the density of water, the beads settle in a 
matter of seconds. This creates obvious issues when attempting to inject beads into a 
microfluidics chip at a uniform rate. We utilize two different methods to keep the beads 
evenly suspended in solution during the DropSeq run. The first method involves 
mechanical agitation and the second method involves density matching using OptiPrep.  
 
Mechanical Agitation 
In the original DropSeq method, a V&P Scientific VP 710 magnetic stirrer was used to 
agitate the beads solution, contained within a syringe, via a small magnetic stir disc. The 
downside to this method is that the force of the magnetic stir disc can shear the beads. In 
fact, we have observed portions of beads contained within the same droplet as another 
intact bead, potentially leading to one cell transcriptome being associated with two 
different barcodes. Utilizing the pressure pumps allows us to place a magnetic stir bar 
within the pressure chamber, but outside of the 1.5mL centrifuge tube. Placing the VP 
710 magnetic tumble stirrer in front of the pressure pump rotates the stir disc and, 
consequently, the microfuge tube. When the dip tube is inserted into the microfuge tube, 
the soft plastic of the tubing acts as the stirring apparatus and results in significantly 
reduced bead shearing (Fig. 6). In spite of this mechanical agitation, we still notice a 
small amount of bead settling by the end of a DropSeq run. 
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Fig. 6: Mechanical agitation to keep the beads suspended. A magnetic stir bar is placed 
within the pressure chamber and is rotated by a VP 710 magnetic stirrer placed in front of 
the chamber. The soft plastic of the dip tube stirs the solution to keep the beads 
suspended. 
 
Density Matching 
The second method we have used to keep the beads suspended is density matching the 
carrier fluid to the beads. To do this, we have augmented the standard DropSeq bead 
buffer with 65% OptiPrep. The bead solution is now composed of: 
• 650uL OptiPrep (Sigma D1556) 
• 150uL 40% Ficoll PM-400 (GE 17-0300-10) 
• 10uL 20% Sarkosyl (Sigma L9150) 
• 40uL 0.5M EDTA 
• 100 uL 2M Tris pH 7.5 
• 50uL 1M DTT 
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By opting for density matching instead of mechanical agitation, we are able to run larger 
volumes of solution without stopping. Additionally, the beads are less likely to settle 
within the tubing/microfluidics and cause a clog. The downside to this approach is that 
the high density and viscosity of the OptiPrep solution causes increased jetting at the 
flow-focusing junction (some droplets don’t pinch off directly at the junction). This 
results in a reduced monodispersity and lower emulsion quality. The reduced 
monodispersity can cause some droplets to have different amounts of reagents compared 
to others, although the ratio of bead/lysis buffer and cell buffer should be constant within 
all the droplets due to the constant flow rate of fluid injection. 
 
The Final Droplet Generation System 
Putting all of the microfluidic components together, we end up with the system shown in 
Fig. 7. We use flow rates of 30 uL/min for both aqueous lines, and 166 uL/min for the 
carrier oil. With these flow rates, we are able to process 1mL of aqueous sample in about 
30 min. At a cell and bead loading density of 100,000/mL, this results in about 5,000 
droplets that captured both a bead and a cell. 
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Fig. 7: The DropSeq system including 3 pressure pumps and associated flow meters, 
microscope, and microfluidics chip. The resulting emulsion is photographed as a phase 
contrast image overlaid on a fluorescence image in order to illustrate droplets containing 
a bead (marked A), a cell (marked B), and both a cell and a bead (marked C). 
 
Emulsion Analysis 
After the emulsion is generated, we take a few uL of the droplets and analyze them on a 
fluorescence microscope. When we stain the cells with Calcein green at 1:500 before 
loading them onto the microfluidics platform, the droplets encapsulating a lysed cell 
fluoresce nicely (Fig. 7). By quickly looking at the emulsion, it is possible to get a 
general sense of the monodispersity as well as capture efficiencies for both beads and 
cells. Loading at 100,000 per mL gives a capture rate on the order of 5%. 
 
Breaking Droplets and Isolating Beads 
After verifying that cells and beads were captured correctly, we break the emulsion by 
adding 30mL of 6X SSC with 1mL of Perfluoro-octanol (Sigma 370533) and shake 
vigorously 5-6 times. In order to isolate the beads, the original DropSeq method 
centrifuges the resulting solution then kicks the beads back into solution for transfer. This 
process is inefficient and loses about half of the beads into the interface. We have 
Fig.7
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achieved much higher recovery by filtering the beads out from the solution. We use a 
30um filter (PluriSelect 43-50030-03) attached onto a 2L conical flask via a self-designed 
vacuum adapter that was 3D-printed with ABS and polished/sealed with acetone (Fig. 
8A). The OpenSCAD file for the design is found in Appendix I. By filtering about 15mL 
at a time, and mechanically agitating the solution between the short 15mL bursts, very 
little precipitate accumulates on the filter and instead ends up in the waste collection. We 
proceed to wash the beads on the filter by flowing through about 60mL of 6X SSC 
(ThermoFisher 15557-036). 
To collect the captured beads, we take off the filter, flip it over, and attach it to 
another self-designed adapter that screws onto a 50mL conical tube and utilizes a vacuum 
to backflow 6X SSC into the collection tube. This adapter was also 3D-printed in ABS 
and sealed/polished with acetone (Fig. 8B-8C), and the OpenSCAD file is in Appendix I. 
We backflow 30mL of 6X SSC, 5-10mL at a time. The beads are then sedimented by 
spinning at 1,000g for 1min. with the centrifuge brake set at 50%. All but about 1mL of 
the 6X SSC is removed, and then the beads are resuspended and transferred to a 1.5mL 
non-stick microfuge tube (VWR 80077-232). The beads are washed twice with 1mL 6X 
SSC, then once with about 200 uL of 5X RT Buffer (ThermoFisher EP0753), and finally 
we proceed with the RT. 
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Fig. 8: (A) The vacuum filtration apparatus for isolating the beads. (B) The attached 
backflow apparatus for recovering filtered beads. (C) A closer view of the backflow 
apparatus. 
 
Reverse Transcription and Template Switching 
The beads are suspended in the following mix to perform the RT and the template 
switching: 
• 75uL water 
• 40uL 5X RT Buffer (ThermoFisher EP0753) 
• 40uL 20% Ficoll PM-400 (GE 17-0300-10) 
• 20uL 10mM dNTPs (ClonTech 639125) 
• 5uL RNase Inhibitor (Lucigen 30281) 
• 10uL 50uM Template Switch Oligo (Appendix V) 
• 10uL Maxima H- RTase (ThermoFisher EP0753) 
The beads are then incubated on a rotator for 30 min. at room temperature followed by 90 
min. on a rotator at 42C. To stop the reaction, the beads are washed once with TE/0.5% 
SDS followed by two washes with TE/0.01% Tween-20. 
Fig 8
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The RT is performed at a lower temperature and slightly longer time than the 
manufacturer’s suggested protocol in order to promote long transcript cDNA synthesis 
and Template Switch Oligo annealing. The template switching relies on the tendency of 
MMLV’s terminal transferase activity to add predominantly dCTPs 33. The Template 
Switch Oligo contains a complementary string of 3 G RNA nucleotides, which anneals to 
the C nucleotides added to the first strand cDNA. The MMLV now performs a second 
transcription reaction and completes the first-strand cDNA, with adapters now on both 
ends (Fig. 9). 
 
Fig. 9: Diagram of the RT reaction on the beads. After capturing an mRNA molecule via 
a poly-T sequence, the RT enzyme synthesizes the first strand cDNA complementary to 
the mRNA and adds a sequence of C’s to the end. The Template Switch Oligo anneals to 
the CCC sequence and contains the reverse of the sequence found on the beads. A second 
RT takes place and a second adapter is synthesized onto the cDNA, whose sequence is 
the reverse complement of the adapter on the bead. 
 
In-Droplet Reverse Transcription 
To perform the RT step in the droplets before the emulsion is broken, we flow all 
necessary reagents in with the cells and beads. The bead buffer is composed of: 
• 10uL IGEPAL (Sigma I8896) 
CCCTTTTT
GGG
Adapter sequence on beads
Cell barcode and UMI
First RT - cDNA synthesis
mRNA from cell
Second RT - reverse complement of bead adapter sequence
Template Switch Oligo
Bead Oligo
Reverse of adapter sequence on beads
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• 630 uL OptiPrep (Sigma D1556) or water 
• 360 uL 5X RT Buffer (ThermoFisher EP0753) 
The cell suspension buffer is composed of: 
• 100uL 50uM Template Switch Oligo (Appendix V) 
• 20 uL 100mM dNTPs (Clontech 639132) 
• 50 uL RNAse Inhibitor (Lucigen 30281) 
• 50 uL RTase (ThermoFisher EP0753) 
• 780 uL PBS with 0.1% BSA 
All reagent flow rates in the microfluidics setup were the same as previously mentioned. 
The droplets were collected in a 15mL conical centrifuge tube, and then a layer of 
mineral oil was added over the top to prevent evaporation. The tube was incubated at 
room temperature for 30 min. then at 42C for 90 min. 5mL of 6X SSC and 1mL of 
perfluorooctanol was added. The tube was capped and vigorously shaken 5-6 times in 
order to break the emulsion. The beads were filtered out as previously described, then 
washed once with TE/0.5% SDS followed by two washes with TE/0.01% Tween-20. 
 
Exonuclease and PCR 
After the RT, the beads are washed with 1mL Tris/pH 8.0 and then added to an 
exonuclease mixture in order to remove the bead primers that did not bind the Poly-A tail 
of an mRNA. The exonuclease mixture consists of: 
• 20uL 10X Exo I Buffer (NEB M0293) 
• 170uL water 
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• 10uL Exo I (NEB M0293) 
After incubating at 37C for 45 min. on a rotator, the beads are washed with 1mL 
TE/0.5% SDS to stop the reaction, then twice with 1mL TE/0.01% Tween-20. 
The beads are now ready for the PCR amplification of barcoded mRNA. 
When preparing a library for sequencing, it is prudent to bear in mind the number 
of reads one will obtain, and the sequencing depth desired on a per-cell basis. We aim for 
at least 50,000 reads per cell, although cellular subgroups have been ascertained with as 
little as 12,000 reads per cell 24. For the purposes of a rough calculation, we expect 200 
million reads from an Illumina HiSeq. Only about 50-60% of these reads end up being 
used in the final analysis (some reads contain too many errors, are not mapped to the 
transcriptome, or are associated with low-coverage barcodes), thus giving us about 100 
million usable reads. To sequence cells at 50,000 reads per cell, we would have to load a 
library containing data from about 2,000 cells onto the sequencer. At a 5% cell capture 
rate, this corresponds to a library generated from about 40,000 total beads. After all 
processing steps, most of our samples have far greater than 40,000 beads, and thus would 
overload the sequencer if we were to generate a library from everything we processed. In 
order to generate a usable library, we aliquot the beads into separate PCR reactions, each 
containing about 10,000 beads. With a standard 5% cell capture rate, each PCR tube 
should contain material from about 500 cells. 
After washing the beads in water and counting with a Fuchs-Rosenthal 
Hemocytometer (inCyto DHC-F01), we set up a PCR reaction with the following 
reagents in each tube: 
	27 
• 10,000 beads 
• 24.2uL water 
• 0.8uL 50uM PCR primer (Appendix V) 
• 25uL 2X Kapa HiFi Hotstart Readymix (Kappa KK2602) 
We run the following PCR program on a Biorad T100 thermal cycler with the heated lid 
set at 105C: 
• 95C 3 min. 
• 4 cycles: 
o 98C 20 sec. 
o 65C 45 sec. 
o 72C 3 min. 
• 9 cycles: 
o 98C 20 sec. 
o 67C 20 sec. 
o 72C 3 min. 
• 72C 5 min. 
• 4C forever 
The PCR adapter sequence is the exact same as the sequence found on the beads. As 
such, the PCR will only amplify cDNA that has successfully undergone two rounds of 
RT, with a full adapter sequence added to the 3’ end that is the reverse complement of the 
sequence on the beads. 
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Upon completion of the PCR, we purify the PCR product using Agencourt 
AMPure beads according to the following protocol: 
• Add 40uL room temperature magnetic beads (0.8X by volume) 
• Incubate 5 min. room temperature 
• Put on magnetic separation stand (V&P Scientific VP 772F4), 1 min. 
• Remove aqueous phase, leaving behind magnetic beads 
• Add 200uL fresh 70% EtOH while still on magnetic stand 
• Aspirate EtOH 
• Repeat for a total of 2 washes with EtOH 
• Air-dry for about 1 min. to remove residual EtOH 
• Remove from magnetic stand 
• Add 20uL water to elute 
• Incubate 2 min. room temperature 
• Put PCR strip back onto magnetic stand 
• After beads separate from eluate, transfer 18uL eluate to a new clean tube 
Using a 0.8X ratio of magnetic beads to PCR product should efficiently remove most 
contaminating products under 300bp, while having little detrimental effect on products 
over 300bp. The original DropSeq protocol calls for a 0.6X ratio of beads 24, but this can 
significantly reduce the recovery of cDNA, as well as being highly intolerant of minor 
pipetting errors 34. After cleanup, the amplified cDNA is now ready for tagmentation. 
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Tapestation and Tagmentation 
In order to evaluate the quality of the amplified cDNA, we run the samples on an Agilent 
Tapestation 2200 instrument with the High Sensitivity HS5000 DNA Screentape. We 
quantify the region from 250bp to 4500bp, and use 600-1,000 pg of DNA as input into 
the tagmentation reaction. The tagmentation reaction utilizes two transposomes that cut 
double stranded DNA and insert a predetermined sequence at the cut site. For the 
tagmentation process, we utilize the reagents from Illumina Kit FC-131-1096. We load 
the DNA, brought up in 5uL water, with 10uL of Nextera Tagment DNA buffer and 5uL 
of Amplicon Tagment enzyme. We incubate this at 55C for 5 min. then immediately add 
5uL of NT neutralization buffer and mix thoroughly. After incubating at room 
temperature for an additional 5 min., we prepare for PCR by adding the following to each 
tube: 
• 15uL NPM Nextera PCR Mix 
• 8uL water 
• 1uL 10uM P5 primer (Appendix V) 
• 1uL 10uM P7 barcoding oligo (Appendix V) 
And run the following PCR program: 
• 72C for 3 min. 
• 95C for 30 sec. 
• 12 cycles of: 
o 95C for 10 sec. 
o 55C for 30 sec. 
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o 72C for 30 sec. 
• 72C for 5 min. 
• 4C forever 
In the original DropSeq method, the initial 72C extension step was eliminated. However, 
the official Illumina method for the XT Library preparation kit where these reagents 
come from recommends the initial extension step. The P5 primer used in the PCR 
includes the requisite Illumina P5 sequence, as well as a sequence that is identical to the 
adapter sequence on the beads and cDNA. This ensures that the only tagmented cDNA 
that gets amplified was only cut once. Thus, everything that is amplified includes the 
initial cell barcode and UMI. The P7 barcoding oligo includes the requisite P7 sequence, 
the tagmentation adapter sequence, and a Nextera index. The inclusion of the Nextera 
index allows us to sequence multiple libraries on one sequencing flowcell, potentially 
from different samples and/or conditions. 
 
Sequencing 
The libraries were sequenced either on an Illumina MiSeq or HiSeq system at one of 
three facilities: 
• BioPolymers Facility of Harvard Medical School 
• NextGen DNA Sequencing Core from the Department of Molecular Biology at 
MGH 
• CCIB DNA Core Facility of MGH 
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The libraries were sequenced with a custom read1 primer, and demultiplexing of reads 
specified by standard Nextera indices associated with read1 (indices used were either 
N701, N702, or N703). The sequencing was always paired-end, with read1 containing the 
cell barcode and UMI, and read2 containing the captured transcript sequence. We 
sequenced read1 to 30bp, and used the rest of the Illumina kit on read2. We have 
frequently used 150 and 300 cycle kits on the MiSeq, which yields well over 100bp of 
transcript sequence, more than enough to unambiguously identify the transcript. 
 
Computational Analysis – Tagging, Mapping, DGE Generation 
The bulk of the computational analysis was performed on the Partners Healthcare Erisone 
computing cluster. The Linux cluster employs the Platform LSF job scheduler to push 
compute jobs to all the different nodes, but the majority of the jobs were pushed to our 
own node. The key specs are: 
• HP ProLiant DL585 G7 
• 4x AMD Opteron 6282 SE processors – 64 cores in total, 2.6 GHz 
• 256GB DDR3/1066MHz RAM 
• All working data stored on networked Panasas storage array 
• Red Hat Enterprise Linux Server release 6.5 
We have written a Python script to generate the directory structure and create a unique 
LSF job submission file for each DropSeq analysis (Appendix II). The ultimate goal of 
the first part of the analysis is to map the read2 reads to a specific gene, and associate this 
with a unique cell via the cell barcode on read1. The UMI is also used to generate a 
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purely digital representation of the transcript copy counts in each cell. The basic steps to 
accomplish this are as follows: 
• Run FastQC on raw data to ensure sequencing went well 
• Convert fastq files to bam 
• Tag read2 data with the cell barcode from bases 1-12 in read1 
• Tag read2 data with the UMI from bases 13-20 in read1 
• Throw out read1 reads, keeping only tagged read2 data 
• Remove reads which have low quality scores associated with the barcode region 
• Trim off any adapter sequence 
• Trim off any Poly-A tail 6bp or longer 
• Copy the data from the bam file into a fastq file to feed into the aligner 
• Use STAR to align the reads to the genome of interest 
• Sort the aligned bam file by queryname 
• Merge the aligned and sorted bam file with the previously tagged bam file to 
recover both the alignment and the cell/UMI tags into one file 
• Label a read with the corresponding gene name if the read aligns to an exon 
• Fix barcode synthesis errors 
• Generate a Digital Gene Expression matrix based on the number of unique UMIs 
reported for a given gene for each cell barcode 
There are three main sets of tools used to accomplish this. One set of tools was published 
in the DropSeq publication 24. We also utilize a set of general purpose sequencing data 
manipulation tools called Picard 34. Lastly, we utilize STAR for the mapping 35. STAR 
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requires the user to generate a genome index for each species one wishes to map to. This 
is relatively simple for a unique species, but in the case of our species-mixing 
experiments, we needed to generate a genome index containing both human and mouse 
genomes, each uniquely labeled. We accomplished this by first writing a Python script to 
tag both the genome fasta files and the GTF annotation files with either “homo” or “mus” 
for human and mouse genomes, respectively. Each fasta entry in the genome files had the 
species tag prepended to the current name, while each entry in the GTF files had the 
species tag prepended to both the seqname field and the gene_name attribute. The tagged 
genome and GTF files were then combined and fed into STAR to generate the requisite 
index files. 
In order to fix the barcode errors, we utilized the tool contained in the DropSeq 
analysis suite named DetectBeadSynthesisErrors. The algorithm from this tool searched 
for any highly represented base in a given position in the pool of UMIs for any given cell 
barcode. If it detects a high representation of “T” at the end of the UMIs (representing the 
beginning of the poly-T tail), it makes the assumption that there was a base missing in the 
cell barcode. From our own analysis, this is an accurate assumption for the batches of 
beads we received: the base is indeed most likely missing from the cell barcode, and not 
from the UMI. In the case of a missing base from the cell barcode, this tool cuts the cell 
barcode short, to contain the first 11 bases of read1, and appends an N to the end. It also 
shifts the UMI so that it contains bases 12-19 of read1, thus fixing the UMI and 
associating it with the correct (albeit shorter) cell barcode. 
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Computational Analysis – Run Metrics, Grouping, Differential Expression 
After generation of the DGE matrix, the rest of the analysis is done locally on a MacBook 
Pro with the RStudio software suite 36. We utilize the edgeR software suite 37 to convert 
the DGE counts matrix into a matrix of CPMs, and follow this with the Seurat software 
suite 38 for single cell analysis. The basic analysis proceeds as follows: 
• Examine cumulative sum plots to estimate the number of cells sequenced 
• Examine bead error distributions to ensure data integrity 
• If analyzing multiple datasets, merge together 
• Convert raw counts to CPM 
• Filter out genes with no associated data or extremely low expression across all 
cells 
• Convert CPM to log-CPM and import into Seurat 
• Identify highly variable genes 
• Isolate principal components 
• Utilize the Jackstraw method 39 to determine significant PCs 
• Map cells based on significant PCs into a two-dimensional map using t-
Distributed Stochastic Neighbor Embedding (t-SNE) 40 
• Identify groups of cells in the t-SNE plot based on density clustering 41 
• If grouping is successful, search for markers of groups 
• Visualization of markers 
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PDX Mouse Model Generation 
The single-cell suspension was injected into NSG-SGM3 mice purchased from Jackson 
Laboratories. NSG-SGM3 mice are triple transgenics that express human IL3, GM-CSF 
and SCF. They are highly immunodeficient but have cytokines that support stable 
engraftment of myeloid and T-reg cells 42. 50uL of cell suspension containing 200 
thousand to 1 million cells (depending on cell availability) was injected intramuscularly 
into the thigh. When either bone marrow or a vial of whole blood was also collected, a 
portion of the mice had the patient immune system reconstituted with PBMCs or CD3-
depleted hematopoietic bone marrow cells. If, after a few weeks, a tumor was felt upon 
palpation, the mice were imaged using a CT scanner to observe the tumor and extent of 
ossification. 
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RESULTS 
Species Mixing Experiments 
The obligatory first experiments to perform with a new DropSeq setup are species mixing 
experiments, where cells from two different species are mixed together in a one-to-one 
ratio before droplet encapsulation. After sequencing, the reads are mapped to a combined 
genome from the two species (in our case, mouse and human). Examining the distribution 
of mouse transcripts and human transcripts for each cell barcode will demonstrate 
whether there was any significant number of double cell encapsulations. When the vast 
majority of cell barcodes contain only human, or only mouse transcripts, it indicates that 
the microfluidics are performing as expected. An example of a successful DropSeq run 
with MEFs and HEK293 is shown in Fig. 10A, while an example of a DropSeq run which 
likely contained overloaded HEK293 cells is shown in Fig. 10B. 
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Fig. 10: Examples of successful (A) and unsuccessful (B) species mixing experiments. 
(B) demonstrates what happens if a cell type (in this case, human) is overloaded: human 
transcripts end up associated with almost every single cell barcode. Note that the 
algorithm used to detect a cell barcode as associated with both species depends on a 
relatively low number of barcodes with combined cell types; the algorithm does not 
perform well when there is an excessive number of barcodes containing high numbers of 
transcripts from both species. 
 
A
B
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OptiPrep Testing 
Utilizing OptiPrep to keep the beads suspended while flowing through the microfluidics 
presents a more robust and user-friendly approach than mechanical agitation. Given the 
benefits, we wanted to test if OptiPrep influenced the DropSeq process in any way. To 
test this, we performed DropSeq on HEK293 and MEFs, both with and without OptiPrep. 
Upon sequencing, we observed no discernible differences in cell doublet rates between 
OpriPrep and No Optiprep (Fig. 11A) After separating out the HEK293 and MEF cell 
barcodes, we isolated the significant PCs and mapped these onto a tSNE plot. The tSNE 
algorithm is a nonlinear dimensionality reduction technique that attempts to reduce high-
dimensionality data into two or three dimensions that can be plotted in a scatter plot 40. 
Our specific application reduces the high dimensionality gene expression level data into 
two dimensions. The final output of the tSNE reduction is a set of x and y coordinates for 
each individual cell, which we plot on a scatter plot. The more closely related two cells 
are, the closer their resulting points should be in the two-dimensional plot. The results are 
shown in Fig. 11B-C. 
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Fig. 11: Comparisons between performing DropSeq with and without OptiPrep. (A) 
Species mixing experiment with HEK293 and MEF. (B) tSNE plot with the MEF cells. 
(C) tSNE plot with the HEK293 cells. In the tSNE plots, blue dots represent the cell 
barcodes from a sample run with OptiPrep, and red dots represent cell barcodes from a 
No OptiPrep sample. 
 
In-Droplet Reverse Transcription 
Only one in-droplet RT test has been sequenced, and the results from the species-mixing 
plot are shown in Fig. 10B. The results appear to show an overloading of human cells, 
and thus more testing is required to optimize the in-droplet RT procedure. At a minimum, 
however, we can conclude that the reverse transcription of the mRNA performed in a 
droplet succeeded in producing cDNA that can be sequenced. 
Fig 11
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Osteosarcoma Sequencing 
An osteosarcoma sample was obtained from the MGH Orthopaedics department on 
October 14, 2015, and run through the DropSeq protocol the same day. The resulting 
libraries were sequenced first on an Illumina MiSeq, then twice on an Illumina HiSeq. 
The two HiSeq runs sequenced the same library, and thus the cell barcodes common to 
both resulting DGE matrices were combined in an additive fashion. The combined DGE 
matrix from the HiSeq runs was merged with the DGE matrix from the original 
exploratory MiSeq run, and the resulting matrix was processed using Seurat. Upon 
removing all cell barcodes containing fewer than 500 expressed genes, and all genes 
expressed in fewer than 2 cells, we were left with 16,653 genes across 795 samples. After 
performing a jackstraw test and selecting only the PCs with a p-value below 0.05, we 
were left with 10 PCs with which to run the tSNE algorithm. When projecting the cells 
onto a tSNE plot, we obtain the results shown in Fig. 11B.  
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Fig. 12: (A) Species mixing experiment from a human osteosarcoma obtained on 
December 22, 2015 with MEFs. (B) tSNE plot from human osteosarcoma obtained on 
October 14, 2015. The cells labeled “Orig” were sequenced on a MiSeq, while the cells 
labeled “DS3-Merge” were sequenced twice on a HiSeq. DropSeq was performed both 
with and without OptiPrep. 
 
 
A second osteosarcoma sample was obtained on December 22, 2015 and sequenced on a 
MiSeq on January 30, 2016. The tumor was dissociated into single cells, and run through 
Fig 12
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the DropSeq protocol with a 1:1 mix of MEFs. The resulting library was sequenced on a 
MiSeq, and the results from the Species Mixing test are shown in Fig. 12A. Notably, the 
transcript counts from nearly all the human osteosarcoma barcodes are very low; after 
removing all cells with less than 500 genes and all genes expressed in less than 2 cells, 
we are left with only 1,534 genes across 13 cells. Although this is too little data to 
analyze on its own, we were able to add this limited data into the analysis with the other 
osteosarcoma and PDX data (Fig. 15C). 
A third osteosarcoma sample was collected on December 2, 2015, processed 
through DropSeq, and sequenced on a MiSeq on March 8, 2016. After performing our 
standard filtration process, we are left with 7,111 genes across 123 cells. When we add 
this data into the dataset with the other two osteosarcoma samples and the PDX data, we 
obtain the tSNE plot shown in Fig. 15C. 
 
Incorporating Mouse PDX Data 
A single cell suspension from the osteosarcoma sample on October 14, 2015 was 
injected, intramuscularly, into 3 different NSG-SGM3 mice. One of the mice also 
received PBMCs isolated from the patient. All three mice developed slightly ossified 
tumors at the site of the injection (Fig. 13). The tumors from the two mice that did not 
receive PBMCs grew quickly, while the tumor in the mouse that received the PBMCs is 
relatively smaller and exhibits significantly retarded growth that has not changed since 
the original tumor could be felt via palpation (Fig. 13B-C). We were not able to extract a 
high quality single cell suspension from one of the mice that did not receive PBMCs, 
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while the other was euthanized, the tumor dissected, and sequenced via DropSeq. The last 
mouse with the PBMCs is still alive, 5 months post-injection, and will be euthanized for 
analysis soon. 
 
Fig. 13: CT Scan showing the tumor growth (67 days post injection) in the mouse 
without PBMCs where we have extracted and sequenced the tumor (A), and the mouse 
with injected PBMCs at 67 days post-injection (B) and 141 days post-injection (C). 
 
The DropSeq library from the PDX mouse has been sequenced initially on a MiSeq, and 
analyzed both on its own and in conjunction with the original osteosarcoma data. Upon 
the initial species analysis, we find about 5 times as many cell barcodes associated with 
human transcripts as compared to those associated with mouse transcripts (Fig. 14A). 
After separating out the mouse cells and looking for CD genes, we find significant 
expression of only CD44, CD81, CD47, CD200, and CD63 (Fig. 14B). When performing 
the human analysis without the original osteosarcoma data, there was enough distinct 
grouping to perform a density clustering analysis (Fig. 15A), however when adding in the 
Fig. 13
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original osteosarcoma data, there was not enough resolution in the combined dataset 
(17,298 genes across 1,126 cells) to perform a density clustering analysis (Fig. 15B). 
Upon testing for differential expression between the PDX cells and the original tumor 
cells, we apply an ROC test to determine the power of each gene (1 minus the probability 
of a type II error on the null hypothesis that the AUC of two groups is the same), and 
attain the results shown in Table 1. 
Although the resolution does not appear high enough to perform a density 
clustering analysis, it is possible to examine the distribution of known markers in the 
tSNE plot. Fig. 16 shows the distribution of a couple immune CD markers, as well as 
FAP and VIM in the combined human osteosarcoma and complementary mouse PDX 
model dataset. 
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Fig. 14: (A) Plot showing distribution of human and mouse transcripts per cell barcode 
for the mouse PDX data obtained from the human osteosarcoma on October 14, 2015. (B) 
Violin plots showing expression of CD markers in only the cell barcodes associated with 
mouse transcripts. 
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Gene AUC Average Diff. Power 
COL3A1 0.095 -6.764291957 0.81 
RPL41P2 0.203 -2.669860277 0.594 
IER3 0.211 -3.773204294 0.578 
RPS11P5 0.228 -3.964412351 0.544 
NFKBIA 0.239 -2.596755554 0.522 
RP3-417G15.1 0.25 -3.045273989 0.5 
MMP9 0.276 -6.389901293 0.448 
HLA-B 0.279 -3.219668179 0.442 
RP11-36C20.1 0.287 -2.277795706 0.426 
RPS19P1 0.294 -4.977252785 0.412 
RP4-765C7.2 0.296 -3.660222274 0.408 
RPL34P27 0.297 -2.710559735 0.406 
COL6A3 0.299 -4.850925875 0.402 
RPL13AP6 0.304 -3.024367707 0.392 
POSTN 0.305 -6.445893147 0.39 
ZFP36 0.308 -2.450306286 0.384 
RPL21P4 0.311 -3.387744285 0.378 
RP4-604A21.1 0.316 -5.043033279 0.368 
CXCL8 0.319 -6.237862621 0.362 
INHBA 0.325 -2.27768765 0.35 
Table 1: Top differentially expressed genes between the PDX cells and primary 
osteosarcoma cells, sorted by power according to the ROC test. 
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Fig. 15: (A) tSNE plot of the human cells from the mouse PDX model from the human 
osteosarcoma obtained on October 14, 2015, grouped with density clustering. (B) tSNE 
plot of mouse PDX data added in to the original sequencing data. Cells from the PDX 
model are colored in red. (C) tSNE plot with the osteosarcoma data from three patients 
and the PDX data from one mouse. Cells labeled “Orig” are from a MiSeq dataset on the 
first tumor, and cells labeled DS3 are from the large HiSeq dataset on the first tumor. 
Cells labeled DS13 are from the small dataset from the second tumor. Cells labeled DS8 
are from the third tumor we sequenced. Cells labeled DS14 are from the mouse PDX 
model. 
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Fig. 16: tSNE plot of the human osteosarcoma sample from October 14, 2015 and the 
complementary mouse PDX model. The cells are colored according to expression of the 
genes FAP, VIM, CD4, and CD14. Red signifies high expression, and yellow signifies 
low expression. 
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DISCUSSION 
DropSeq Method Improvements 
After much trial and error, we have managed to improve on the original DropSeq 
protocol in a few notable ways. We have successfully utilized a reusable glass 
microfluidics chip, switched to pressure pumps instead of syringe pumps, implemented a 
bead suspension system that uses OptiPrep (a density matching reagent) instead of 
mechanical agitation, improved the bead isolation step, and begun to implement an in-
droplet reverse transcription approach. By using a glass microfluidics chip instead of 
PDMS, the per-run consumables cost decreases significantly. Importantly, this is an off-
the-shelf chip from a large manufacturer, providing far easier access for the general 
public than synthesizing a custom PDMS chip. Also, complementing glass microfluidics 
with pressure pumps vastly simplifies the system set-up time and increases throughput. 
By utilizing OptiPrep instead of a magnetic stir disc, we are able to significantly reduce 
microfluidics channel clogging, as well as bead shearing. The downside to this is the high 
viscosity of OptiPrep. This large difference in viscosity between the beads and cells 
solutions causes a slight reduction in monodispersity in the resulting droplets. Although 
this is a concern, the benefits outweigh the negatives in our applications. Through the use 
of a precise filter instead of centrifugation to isolate the beads, we are able to greatly 
increase bead recovery rates. Lastly, by performing the reverse transcription within the 
droplets, we are able to significantly reduce the handling of RNA molecules, and thus the 
risk of degradation is vastly reduced. The downside to this in-droplet RT approach is the 
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high cost of consumables, largely due to the amount of MMLV Reverse Transcriptase 
enzyme we must use. 
 
Osteosarcoma Heterogeneity 
Thus far, we only have one osteosarcoma dataset that has been deep-sequenced. Judging 
by the tSNE plot of this osteosarcoma, we see the evidence of extensive heterogeneity, 
although distinct cellular groupings are not yet readily apparent. We postulate this lack of 
grouping is due to a lack of cellular resolution; if we were able to sequence more cells, 
we believe the borders between cellular groups would be more readily distinguishable. 
As the dataset stands, one can begin to see the forming of distinct groups, but the borders 
are not yet concretely defined. 
In an attempt to identify already known cell types within the sequenced results, 
we first examined the immune markers CD4 and CD14, and found relatively low 
numbers of cells expressing these in significant quantities (Fig. 16). Next, we examined 
the Fibroblast Activation Protein gene, a marker for activated fibroblasts in pathologic 
sites 43. We found activated fibroblasts distributed throughout most of the tSNE plot, 
without any clear grouping (Fig. 16). This was not too surprising as we have previously 
established that fibroblasts are highly heterogeneous 44. Last, we also checked for 
expression of Vimentin, which is widely considered a marker for many types of cancers, 
sarcomas in particular 45 46 47 48 12. We found high expression of Vimentin in nearly every 
single cell (Fig. 16), which provides confirmation that we did indeed successfully isolate 
and sequence osteosarcoma cells. 
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The case for heterogeneity is advanced by the inclusion of three separate 
osteosarcoma datasets, from different patients. Our second dataset has a very low 
transcript count and very few cells, but the intertumor heterogeneity is already exhibiting 
interesting characteristics. As one might expect, when looking at the tSNE plot the 
majority of the cells from the second tumor cluster distinctly separate from the first 
tumor. However, there is a small subset of cells that branches far off from the main 
cluster and begins to integrate into the cloud of cells from the first tumor (Fig. 15C). This 
pattern is repeated with the third osteosarcoma tumor that we sequenced; the majority of 
cells from the third tumor cluster distinctly from the other two tumors, yet there is again a 
subset of cells which begins to integrate with the cells from the other tumors (Fig. 15C). 
 
PDX Model – Selection for a Subset of Cells? 
When we projected the cells from the PDX osteosarcoma model onto the same tSNE plot 
as the original osteosarcoma sample, we found the PDX model to exhibit decreased 
heterogeneity as compared to the original sample. However, the PDX model was 
engulfed within the same cloud of cells as the original tumor (Fig. 15B), potentially 
indicating that the PDX model selects for a certain subset of cells with stem-like potential 
from the original population. 
When comparing the expression profiles of cells in the PDX model to the original 
tumor cells, a number of genes are significantly different according to a likelihood ratio 
test based on zero-inflated data. However, the only genes that have moderately high 
power (above 0.4) according to an ROC test are: COL3A1, RPL41P2, IER3, RPS11P5, 
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NFKBIA, RP3-417G15.1, MMP9, HLA-B, RP11-36C20.1, RPS19P1, RP4-765C7.2, 
RPL34P27, and COL6A3 (Table 1). 
The procollagen encoding genes are notable, as studies have previously described 
a potential correlation between collagen and metastatic potential in breast cancer49. 
Importantly, our results are in line with the current literature surrounding type III 
collagen in osteosarcoma: studies have reported generally high, yet heterogeneous, 
expression of collagen III in a primary osteosarcoma 50, yet the expression of collagen III 
is practically nonexistent upon transplantation into a mouse 51. 
The gene IER3, also known as IEX-1, is interesting as well for its potential role in 
neoplasm development and prognosis. IER3 is known to play a pro-apoptotic role in 
many cell types, and its expression level has been suggested as a biomarker and 
prognostic indicator in certain cancers 52 53. Moreover, IER3 has been shown to play a 
role in pharmaceutical resistance in some osteosarcoma xenografts 54. It is conceivable 
that the significant downregulation of IER3 in our PDX model is due to the 
chemotherapy the patient received prior to the primary tumor resection, as chemotherapy 
has been shown to increase IER3 expression in some primary liposarcoma cells 55. 
NFKBIA is a known pro-apoptotic tumor-suppressor gene that acts to inhibit NF-
KB, which is generally associated with worse survival in most solid tumors 56. 
Interestingly, one study has also noted an anti-apoptotic capacity with NFKBIA, and 
found a decreased expression of NFKBIA to yield an increased sensitivity to anticancer 
treatment 57. There have been, however, far more studies detailing the association of 
deletion or silenced expression of NFKBIA with poor prognosis and increased 
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tumorigenesis 58 59. Our observed decrease in NFKBIA expression in the PDX model 
could have important ramifications for the viability of a PDX model as a testing ground 
for anticancer therapies. It could indicate that the xenograft process selects for the most 
aggressive cells in a primary tumor, or, more troubling, that a cell population is selected 
which is more susceptible to therapy than the primary tumor. It is conceivable, as with 
IER3, that the increased expression of NFKBIA we observed in the primary tumor is due 
to the chemotherapy the patient received prior to the tumor resection 55. 
MMP9 is a collagenase that degrades the extracellular matrix. It has been 
implicated in malignant transformation of some cancers 60 and in tumor growth and 
invasion in others 61. Moreover, it is found to be highly expressed in osteosarcoma 
samples 62 and has been suggested as a biomarker for survival 63. The highly differential 
expression observed between the primary tumor cells and the PDX model cells is 
concerning, given its observed importance in some cancers and prognostic indicator 
ability in osteosarcoma. 
The downregulation of HLA-B we observe in the PDX model could be highly 
significant, especially if the mouse has the patient’s immune system reconstituted (the 
mouse which generated this data did not have a reconstituted immune system). The HLA-
B gene encodes for a member of the Major Histocompatibility Complex, class I. There is 
recent evidence suggesting that metastatic tumor cells evade the immune system by 
downregulation of HLA class 1 antigens, and HLA class 1 genes have been proposed as a 
target to entice the host immune system to destroy malignant cells 64 65. Moreover, HLA-
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B has been shown to help regulate apoptosis, proliferation, and cell invasion potential in a 
carcinoma cell line 66. 
 
Conclusions 
By examining the transcriptomic expression profile of osteosarcoma tumors at the single-
cell level, we have confirmed the extensive heterogeneity previously reported on a macro 
level. Moreover, we have propagated one of these osteosarcoma tumors into a mouse 
PDX model, and compared the levels of heterogeneity at the cellular level to the primary 
tumor. What we found presents a potential warning about the selection factors 
unknowingly imposed when creating a PDX model. These unknown selection factors 
could be highly relevant given that many new therapies are being tested in PDX models 
prior to clinical trials. Judging from the tSNE plots, creation of a PDX model selects for a 
certain subset of cells and consequently reduces the original heterogeneity from the 
primary tumor (Fig. 15B), and until this selection process is further studied, it is difficult 
to judge what impact this could have on the results of a PDX study. To illustrate this, we 
have performed a differential expression analysis between PDX single-cell data and the 
primary tumor data. Most of the top hits we have found are known to be very relevant to 
cancer progression, with some of these genes being considered as biomarkers and 
therapeutic targets. It is difficult at this point to determine what exactly is causing these 
differences, but it could likely be due to a combination of the following: lack of a 
functional immune system in the mouse host; prior chemotherapy in the patient; the 
selection of a small subset of cells from the primary tumor which have an expression 
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profile similar to the PDX model, but which are not great enough in numbers to influence 
the bulk comparison between PDX cells and primary tumor cells. Further studies are 
warranted to observe the impact of serial xenografts, immune reconstitution in the mouse, 
and how the observed selection/heterogeneity influences conclusions drawn from PDX 
studies.  
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APPENDIX I – OpenSCAD code 
Vacuum Adapter: 
 
//Increase smoothness 
$fs=0.1; 
$fa=1; 
 
module 1_4_barb(){ 
    difference(){ 
        union(){ 
            cylinder(4,3,3.75); 
            translate([0,0,3]) cylinder(4,3,3.75); 
            translate([0,0,6]) cylinder(4,3,3.75); 
            translate([0,0,9]) cylinder(4,3,3.75); 
            translate([0,0,12]) cylinder(4,3,3.75); 
        } 
        translate([0,0,-1]) cylinder(20,2,2); 
    } 
} 
 
difference(){ 
    difference(){ 
        difference(){ 
            difference(){ 
                union(){ 
                    //Tapered portion to fit into conical flask 
                    cylinder(30,20.5, 23.5); 
                    //Larger tapered portion of main body 
                    translate([0,0,30]) cylinder(20, 23.5,25); 
                    //Add hose barb 
                    translate([40,0,40]) rotate([0,-90,0]) 1_4_barb(); 
                } 
                //Bore out large inner core, but don't go all the way through 
                translate([0,0,-1]) cylinder(h=47,r=15); 
            } 
            //Bore out smaller hole for PluriSelect filter to fit snugly into 
            cylinder(h=100, r=11.5); 
        } 
        //Hole for hose barb 
        translate([10,0,40]) rotate([0,90,0]) cylinder(200, 2, 2); 
    } 
    //Vacuum release hole 
    translate([0,0,40]) rotate([-90,0,0]) cylinder(200, 4, 4); 
} 
 
 
Backflow Adapter: 
 
//Threads module written by Dan Kirshner 
include <threads.scad>; 
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//Increase smoothness 
$fa=1; 
$fs=0.1; 
 
 
module 1_4_barb(){ 
    difference(){ 
        union(){ 
            cylinder(4,3,3.75); 
            translate([0,0,3]) cylinder(4,3,3.75); 
            translate([0,0,6]) cylinder(4,3,3.75); 
            translate([0,0,9]) cylinder(4,3,3.75); 
            translate([0,0,12]) cylinder(4,3,3.75); 
        } 
        translate([0,0,-1]) cylinder(20,2,2); 
    } 
} 
 
 
module base(){ 
    union(){ 
        translate([0,0,9]) { 
            difference(){ 
                //Main body 
                cylinder(4, 27, 27); 
                //Bore out larger inner cylinder, but not all the way through 
                translate([0,0,-1]) cylinder(4, 15, 15); 
                //Bore out smaller cylinder to hold PluriSelect filter snugly 
                translate([0,0,-1]) cylinder(20, 13, 13); 
            } 
        } 
        difference(){ 
            //Thread base 
            cylinder(h=9, r=27); 
            //Bore out threads, like a tap 
            translate([0,0,-1]) metric_thread(diameter=31.5, pitch=3, length=11, internal=true, n_starts=2, 
square=true, rectangle=0.5); 
        } 
    } 
} 
 
barb_hei=7; 
difference(){ 
    difference(){ 
        difference(){ 
            union(){ 
                base(); 
                //Add the hose barb 
                translate([42,0,barb_hei]) rotate([0,-90,0]) 1_4_barb(); 
            } 
            //Bore out connection between barb and main body, but not through the threads 
            translate([18,0,barb_hei]) rotate([0,90,0]) cylinder(20, 2, 2); 
	58 
        } 
        //Vent the barb hole to the top surface 
        translate([12,-2,9]) cube([9,4,20]); 
    } 
    //Connect barb hole to bottom perimeter of PluriSelect filter 
    translate([18,-2,barb_hei]) cube([4,4,20]); 
} 
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APPENDIX II – Python Script to Start Analysis 
import argparse 
import os 
import subprocess 
 
params = { 
    'picard_jar':'', 
    'drop_seq_tools':'', 
    'star_exec':'', 
    'star_genome_dir':'', 
    'genome_fa':'', 
    'genome_annot':'', 
    'lsf_dir':'', 
    'read1':'', 
    'read2':'', 
    'unmapped_bam':'', 
    'sample_name':'', 
    'unmapped_tagged_cell_bam':'', 
    'tagged_cell_summary':'', 
    'unmapped_tagged_cell_molecular_bam':'', 
    'tagged_molecular_summary':'', 
    'unmapped_tagged_filtered_bam':'', 
    'unmapped_tagged_filtered_trimmed_smart':'', 
    'trimming_smart_summary':'', 
    'unmapped_tagged_filtered_trimmed_smart_polya':'', 
    'trimming_polya_summary':'', 
    'unmapped_tagged_trimmed_filtered_fastq':'', 
    'star_out_prefix':'', 
    'num_barcodes_fix':200, 
    'num_final_barcodes':150, 
    'memory':60 
} 
 
command = """ 
#!/bin/bash 
 
#enter your working directory, change to your own dir 
cd {lsf_dir} 
 
# enable your environment, which will use .bashrc configuration in your home directory 
#BSUB -L /bin/bash 
 
# the name of your job showing on the queue system 
#BSUB -J {sample_name} 
 
# the queue that you will use 
# use bqueus command to check the available queues 
#BSUB -q big-multi 
 
 
# the system output and error message output, %J will show as your jobID 
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#BSUB -o %J.out 
#BSUB -e %J.err 
 
#the CPU number that you will collect (Attention: each node has 2 CPU) 
#BSUB -n 16 
 
## Memory reservation in MB 
#BSUB -R rusage[mem={memory}000]   
 
## Threshold at which job is terminated in KB 
ulimit -v {memory}000000 
 
#Finally, Start the programs 
 
java -Djava.io.tmpdir='pwd'/tmp -jar {picard_jar} FastqToSam FASTQ={read1} FASTQ2={read2} 
OUTPUT={unmapped_bam} SAMPLE_NAME={sample_name} 
 
{drop_seq_tools}/TagBamWithReadSequenceExtended INPUT={unmapped_bam} 
OUTPUT={unmapped_tagged_cell_bam} SUMMARY={tagged_cell_summary} BASE_RANGE=1-12 
BARCODED_READ=1 BASE_QUALITY=10 NUM_BASES_BELOW_QUALITY=1 
DISCARD_READ=false TAG_NAME=XC 
 
{drop_seq_tools}/TagBamWithReadSequenceExtended INPUT={unmapped_tagged_cell_bam} 
OUTPUT={unmapped_tagged_cell_molecular_bam} SUMMARY={tagged_molecular_summary} 
BASE_RANGE=13-20 BARCODED_READ=1 BASE_QUALITY=10 
NUM_BASES_BELOW_QUALITY=1 DISCARD_READ=true TAG_NAME=XM 
 
{drop_seq_tools}/FilterBAM INPUT={unmapped_tagged_cell_molecular_bam} 
OUTPUT={unmapped_tagged_filtered_bam} TAG_REJECT=XQ 
 
{drop_seq_tools}/TrimStartingSequence INPUT={unmapped_tagged_filtered_bam} 
OUTPUT={unmapped_tagged_filtered_trimmed_smart} 
OUTPUT_SUMMARY={trimming_smart_summary} 
SEQUENCE=AAGCAGTGGTATCAACGCAGAGTGAATGGG MISMATCHES=0 NUM_BASES=5 
 
{drop_seq_tools}/PolyATrimmer INPUT={unmapped_tagged_filtered_trimmed_smart} 
OUTPUT={unmapped_tagged_filtered_trimmed_smart_polya} 
OUTPUT_SUMMARY={trimming_polya_summary} MISMATCHES=0 NUM_BASES=6 
 
java -Xmx4g -jar {picard_jar} SamToFastq INPUT={unmapped_tagged_filtered_trimmed_smart_polya} 
FASTQ={unmapped_tagged_trimmed_filtered_fastq} 
 
{star_exec} --genomeDir {star_genome_dir} --readFilesIn {unmapped_tagged_trimmed_filtered_fastq} --
outFileNamePrefix {star_out_prefix} 
 
java -Djava.io.tmpdir='pwd'/tmp -jar {picard_jar} SortSam I={star_out_prefix}Aligned.out.sam 
O={star_out_prefix}Aligned_Sorted.bam SO=queryname 
 
java -Djava.io.tmpdir='pwd'/tmp -jar {picard_jar} MergeBamAlignment 
REFERENCE_SEQUENCE={genome_fa} 
UNMAPPED_BAM={unmapped_tagged_filtered_trimmed_smart_polya} 
ALIGNED_BAM={star_out_prefix}Aligned_Sorted.bam 
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OUTPUT={star_out_prefix}Aligned_Sorted_Merged.bam 
INCLUDE_SECONDARY_ALIGNMENTS=false PAIRED_RUN=false 
 
{drop_seq_tools}/TagReadWithGeneExon I={star_out_prefix}Aligned_Sorted_Merged.bam 
O={star_out_prefix}Aligned_Sorted_Merged_Tagged.bam 
SUMMARY={star_out_prefix}Gene_Tagging_Summary.txt ANNOTATIONS_FILE={genome_annot} 
TAG=GE 
 
{drop_seq_tools}/DetectBeadSynthesisErrors I={star_out_prefix}Aligned_Sorted_Merged_Tagged.bam 
OUTPUT_STATS={star_out_prefix}Bead_Error_Detection_Stats.txt 
SUMMARY={star_out_prefix}Bead_Error_Detection_Summary.txt 
O={star_out_prefix}Aligned_Sorted_Merged_Tagged_Fixed.bam 
PRIMER_SEQUENCE=AAGCAGTGGTATCAACGCAGAGTAC 
NUM_BARCODES={num_barcodes_fix} 
 
{drop_seq_tools}/BAMTagHistogram I={star_out_prefix}Aligned_Sorted_Merged_Tagged_Fixed.bam 
O={star_out_prefix}cell_readcounts.txt TAG=XC 
 
{drop_seq_tools}/DigitalExpression I={star_out_prefix}Aligned_Sorted_Merged_Tagged_Fixed.bam 
O={star_out_prefix}DGE.txt SUMMARY={star_out_prefix}Gene_Transcript_Summary.txt 
NUM_CORE_BARCODES={num_final_barcodes}""" 
 
 
 
def main(indir, read1, read2, sample_name, out_dir_base, num_barcodes_fix, num_final_barcodes, 
picard_jar, 
         ds_dir, star_exec, star_genome, genome_fa, genome_ann): 
    my_params = dict(params) 
    my_params['picard_jar'] = picard_jar 
    my_params['drop_seq_tools'] = ds_dir 
    my_params['star_exec'] = star_exec 
    my_params['star_genome_dir'] = star_genome 
    my_params['genome_fa'] = genome_fa 
    my_params['genome_annot'] = genome_ann 
    my_params['lsf_dir'] = out_dir_base 
    my_params['read1'] = '{}/{}'.format(indir, read1) 
    my_params['read2'] = '{}/{}'.format(indir, read2) 
    my_params['unmapped_bam'] = '{}/{}_unmapped.bam'.format(indir, sample_name) 
    my_params['sample_name'] = sample_name 
    my_params['unmapped_tagged_cell_bam'] = '{}/Tagging/{}_tagged_cell.bam'.format(out_dir_base, 
sample_name) 
    my_params['tagged_cell_summary'] = '{}/Tagging/{}_tagged_cell_summary.txt'.format(out_dir_base, 
sample_name) 
    my_params['unmapped_tagged_cell_molecular_bam'] = 
'{}/Tagging/{}_tagged_cell_molecular.bam'.format(out_dir_base, sample_name) 
    my_params['tagged_molecular_summary'] = 
'{}/Tagging/{}_tagged_cell_molecular_summary.txt'.format(out_dir_base, sample_name) 
    my_params['unmapped_tagged_filtered_bam'] = 
'{}/Tagging/{}_tagged_filtered.bam'.format(out_dir_base, sample_name) 
    my_params['unmapped_tagged_filtered_trimmed_smart'] = 
'{}/Tagging/{}_tagged_filtered_trimmed_smart.bam'.format(out_dir_base, sample_name) 
    my_params['trimming_smart_summary'] = 
'{}/Tagging/{}_trimming_smart_summary.txt'.format(out_dir_base, sample_name) 
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    my_params['unmapped_tagged_filtered_trimmed_smart_polya'] = 
'{}/Tagging/{}_tagged_filtered_trimmed_smart_polya.bam'.format(out_dir_base, sample_name) 
    my_params['trimming_polya_summary'] = 
'{}/Tagging/{}_trimming_polya_summary.txt'.format(out_dir_base, sample_name) 
    my_params['unmapped_tagged_trimmed_filtered_fastq'] = 
'{}/Tagging/{}_tagged_filtered_trimmed.fastq'.format(out_dir_base, sample_name) 
    my_params['star_out_prefix'] = '{}/Alignment/{}_'.format(out_dir_base, sample_name) 
    my_params['num_barcodes_fix'] = num_barcodes_fix 
    my_params['num_final_barcodes'] = num_final_barcodes 
     
    for d in [my_params['unmapped_tagged_cell_bam'], my_params['star_out_prefix']]: 
        os.makedirs(os.path.dirname(d), exist_ok=True) 
     
    lsf_file = '{}/{}_DropSeq_Analysis.lsf'.format(out_dir_base, sample_name) 
    out = open(lsf_file, 'w') 
    out.write(command.format(**my_params)) 
    out.close() 
    subprocess.call('bsub < {}'.format(lsf_file), shell=True) 
    return 
 
 
if __name__ == '__main__': 
    parser = argparse.ArgumentParser() 
    parser.add_argument('indir', help='The input directory where your reads are stored.') 
    parser.add_argument('read1', help='The name of your read1 file.') 
    parser.add_argument('read2', help='The name of your read2 file.') 
    parser.add_argument('sample_name', help='The sample name') 
    parser.add_argument('out_base', help='The base folder to contian the output.') 
    parser.add_argument('--num_barcodes_fix', default=600, type=int, help='The number of barcodes to use 
in the fixing algorithm.') 
    parser.add_argument('--num_final_barcodes', default=300, type=int, help='Number of final barcodes to 
output.') 
    parser.add_argument('--org', default='human', help='Specify organism. Options are human mouse both') 
    parser.add_argument('--picard', default=None, help='Location of Picard jar. Default option picks stored 
location.') 
    parser.add_argument('--DS_Folder', default=None, help='DropSeq Tools folder. Default option picks 
stored location.') 
    parser.add_argument('--star_gen', default=None, help='Specify STAR genome directory. Over-rides 
default option picked by org setting.') 
    parser.add_argument('--star_exec', default=None, help='Star executable location. Default option picks 
stored location.') 
    parser.add_argument('--gen_fa', default=None, help='Genome fasta file. Over-rides default option picked 
by org setting.') 
    parser.add_argument('--gen_annot', default=None, help='Genome annotation file. Over-rides default 
option picked by org setting.') 
    x = parser.parse_args() 
     
    if x.org == 'human': 
        star_genome = '/data/seed/Single_Cell/DropSeq/STAR_Human_Reference/' 
        genome_fa = 
'/data/seed/Single_Cell/DropSeq/Ensembl_Genomes/Homo_sapiens.GRCh38.dna.primary_assembly.fa' 
        genome_ann = '/data/seed/Single_Cell/DropSeq/Ensembl_Genomes/Homo_sapiens.GRCh38.81.gtf' 
    elif x.org == 'both': 
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        star_genome = '/data/seed/Single_Cell/DropSeq/STAR_Human_Mouse_Reference/' 
        genome_fa = 
'/data/seed/Single_Cell/DropSeq/Ensembl_Genomes/Human_Mouse_Tagged_Combined.fa' 
        genome_ann = 
'/data/seed/Single_Cell/DropSeq/Ensembl_Genomes/Human_Mouse_Tagged_Combined.gtf' 
    if x.picard: 
        picard_jar = x.picard 
    else: 
        picard_jar = '/data/seed/Programs/Picard/picard-tools-1.138/picard.jar' 
    if x.DS_Folder: 
        ds_dir = x.DS_Folder 
    else: 
        ds_dir = '/data/seed/Single_Cell/DropSeq/Drop-seq_tools' 
    if x.star_gen: 
        star_genome = x.star_gen 
    if x.star_exec: 
        star_exec = x.star_exec 
    else: 
        star_exec = '/data/seed/Programs/STAR/STAR-master/bin/Linux_x86_64_static/STAR' 
    if x.gen_fa: 
        genome_fa = x.gen_fa 
    if x.gen_annot: 
        genome_ann = x.gen_annot 
     
    main(x.indir, x.read1, x.read2, x.sample_name, x.out_base, x.num_barcodes_fix, x.num_final_barcodes, 
picard_jar, 
         ds_dir, star_exec, star_genome, genome_fa, genome_ann) 
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APPENDIX III – Single Cell Analysis in R 
R Markdown file of the analysis with the Mouse PDX data showing sample commands: 
 
--- 
title: "DS_14_Seq1_MouseSarc" 
output: html_document 
--- 
 
This data is from the Miseq. It is from a mouse xenograft from the DS3 tumor. Sequenced Feb. 2, 2016. 
Mapped to both human and mouse genome. 
 
Load required libraries 
```{r} 
library(Seurat) 
``` 
Read in data 
```{r} 
Optiprep<-read.table("/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-Seq/DS14-
MouseSarc/DS14_Seq1_MouseSarc_OP_DGE.txt", header=T, row.names=1) 
OP_CellCounts<-read.table("/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-Seq/DS14-
MouseSarc/DS14_Seq1_MouseSarc_OP_cell_readcounts.txt", header=FALSE) 
``` 
 
Look at CumSum plots to see how many cells we captured 
```{r} 
tmp<-cumsum(OP_CellCounts$V1) 
tmp<-tmp/max(tmp) 
plot(tmp, xlim=c(0,700), ylim=c(0,0.6), main="Optiprep Total Proportion of Reads") 
``` 
 
Lets look at distribution of bead synthesis errors 
```{r} 
OP_BeadStats <- read.table("/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-Seq/DS14-
MouseSarc/DS14_Seq1_MouseSarc_OP_Bead_Error_Detection_Stats.txt", header=TRUE) 
table(OP_BeadStats$ERROR_TYPE) 
hist(OP_BeadStats$SYNTH_MISSING_BASE) 
hist(OP_BeadStats$NUM_UMI, ylim=c(0,50)) 
plot(OP_BeadStats$SYNTH_MISSING_BASE, OP_BeadStats$NUM_UMI) 
``` 
Only barcodes with an error at position 8 are fixed, the rest are tossed. 
 
Look at summed counts, merge data together into one data frame 
```{r} 
colnames(Optiprep)<-paste("Optiprep_", colnames(Optiprep), sep="") 
plot(sort(apply(Optiprep, 2, sum)), ylab="Summed counts", xlab="Cell index", main="Optiprep Flow 
Rates Counts") 
all_data<-Optiprep 
 
``` 
 
Mark human and mouse genes: 
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```{r} 
homo_rows<-substring(rownames(all_data), 1, nchar("homo_")) == "homo_" 
mus_rows<-substring(rownames(all_data), 1, nchar("mus_")) == "mus_" 
mus_sums<-colSums(all_data[mus_rows,]) 
homo_sums<-colSums(all_data[homo_rows,]) 
plot(mus_sums, homo_sums, xlab="Number of Mouse Transcripts", ylab="Number of Human 
Transcripts") 
sum(mus_sums>1000) 
sum(homo_sums>1000) 
my_frame<-data.frame(mus_sums, homo_sums) 
sum(rowSums(my_frame)>10000) 
sum(rowSums(my_frame)>5000) 
my_frame$Cell_Type <- my_frame$mus_sums 
my_frame$Cell_Type[my_frame$mus_sums>my_frame$homo_sums] = "Mouse" 
my_frame$Cell_Type[my_frame$mus_sums<my_frame$homo_sums] = "Human" 
m_m<-mean(my_frame$homo_sums[my_frame$Cell_Type=="Mouse"]) 
m_std<-sd(my_frame$homo_sums[my_frame$Cell_Type=="Mouse"]) 
h_m<-mean(my_frame$mus_sums[my_frame$Cell_Type=="Human"]) 
h_std<-sd(my_frame$mus_sums[my_frame$Cell_Type=="Human"]) 
my_frame$Cell_Type[my_frame$homo_sums>(m_m+5*m_std) & my_frame$mus_sums>(h_m+5*h_std)] 
= "Both" 
 
my_frame$Condition <- rownames(my_frame) 
my_frame$Condition[substring(rownames(my_frame), 1, nchar("NoOptiprep")) == "NoOptiprep"] <- 
"NO" 
my_frame$Condition[substring(rownames(my_frame), 1, nchar("Optiprep")) == "Optiprep"] <- "OP" 
my_colors<-my_frame$Cell_Type 
my_colors[my_colors=="Mouse"]<-rgb(0,0,1,0.5) 
my_colors[my_colors=="Human"]<-rgb(1,0,0,0.5) 
my_colors[my_colors=="Both"]<-rgb(0,1,0,0.5) 
plot(my_frame$mus_sums, my_frame$homo_sums, xlab="Number of Mouse Transcripts", ylab="Number 
of Human Transcripts", main="Number of Human vs. Mouse Transcripts", col=my_colors, pch=16, cex=1) 
legend("topright", c("Mouse", "Human", "Both"), col=c(rgb(0,0,1,0.5), rgb(1,0,0,0.5), rgb(0,1,0,0.5)), 
pch=c(16,16)) 
 
my_colors_condition<-my_frame$Condition 
my_colors_condition[my_colors_condition=="OP"]<-rgb(0,0,1,0.5) 
my_colors_condition[my_colors_condition=="NO"]<-rgb(1,0,0,0.5) 
plot(my_frame$mus_sums, my_frame$homo_sums, xlab="Number of Mouse Transcripts", ylab="Number 
of Human Transcripts", main="Number of Human vs. Mouse Transcripts", col=my_colors_condition, 
pch=16, cex=1) 
legend("topright", c("Optiprep", "No Optiprep"), col=c(rgb(0,0,1,0.5), rgb(1,0,0,0.5)), pch=c(16,16)) 
 
``` 
 
Separate out mouse and human matrix 
```{r} 
homo_rows<-substring(rownames(all_data), 1, nchar("homo_")) == "homo_" 
mus_rows<-substring(rownames(all_data), 1, nchar("mus_")) == "mus_" 
mus_cols<-rownames(my_frame)[my_frame$Cell_Type=="Mouse"] 
homo_cols<-rownames(my_frame)[my_frame$Cell_Type=="Human"] 
Mouse_DGE<-all_data[mus_rows,mus_cols] 
Human_DGE<-all_data[homo_rows,homo_cols] 
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rownames(Mouse_DGE)<-substring(rownames(Mouse_DGE), nchar("mus_")+1) 
rownames(Human_DGE)<-substring(rownames(Human_DGE), nchar("homo_")+1) 
write.table(Mouse_DGE, file="/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-Seq/DS14-
MouseSarc/DS14_Seq1_MouseSarc_OP_Mouse_DGE.txt", quote=F) 
write.table(Human_DGE, file="/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-Seq/DS14-
MouseSarc/DS14_Seq1_MouseSarc_OP_Human_DGE.txt", quote=F) 
``` 
 
Convert to CPM and analyze Mouse cells on their own: 
```{r} 
library(edgeR) 
library(Seurat) 
y<-DGEList(Mouse_DGE) 
my_cpm<-cpm(y) 
my_cpm[is.na(my_cpm)]<-0 
keep <- rowSums(my_cpm>1) >= 5 
sum(keep) 
y<-y[keep,] 
dim(y) 
y$samples$lib.size<-colSums(y$counts) 
my_cpm<-cpm(y) 
my_cpm[is.na(my_cpm)]<-0 
corner(my_cpm) 
seur_cpm<-new('seurat', raw.data=as.data.frame(log(my_cpm+1))) 
seur_cpm<-setup(seur_cpm, project="MouseSarc_Mouse", names.field=1, names.delim="_", min.cells=2, 
min.genes=500, is.expr=1) 
seur_cpm 
seur_cpm=mean.var.plot(seur_cpm, y.cutoff=2, x.low.cutoff=2,fxn.x=expMean, fxn.y=logVarDivMean) 
seur_cpm<-pca(seur_cpm, do.print=FALSE) 
viz.pca(seur_cpm, 1:4) 
seur_cpm <- jackStraw(seur_cpm, num.replicate=200, do.print=FALSE) 
jackStrawPlot(seur_cpm, PCs=1:18) 
``` 
 
I don't think we have enough cells to make any significant statments. Most of the PCAs are statistically 
insignificant. Pick the only significant PCs. 
```{r} 
pc_use<-c(1:3, 5) 
seur_cpm<-run_tsne(seur_cpm, dims.use=pc_use, max_iter=2000) 
tsne.plot(seur_cpm, pt.size=3) 
seur_cpm@var.genes 
#doHeatMap(seur_cpm,genes.use = seur_cpm@var.genes,slim.col.label = TRUE,remove.key = 
TRUE,cexRow=0.1) 
vlnPlot(seur_cpm, c("Cdk11b", "Cd14", "Cd151", "Cd164", "Cd200", "Cd248", "Cd24a", "Cd276", 
"Cd2ap", "Cd2bp2", "Cd302", "Cd34", "Cd38", "Cd3eap", "Cd44", "Cd47", "Cd55", "Cd59a", "Cd63", 
"Cd68", "Cd72", "Cd81", "Cd84", "Cd9", "Cd93", "Cd99l2")) 
genePlot(seur_cpm, "Cd47", "Cd44") 
``` 
 
Do the same, but with the Human cells: 
```{r} 
library(edgeR) 
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library(Seurat) 
y<-DGEList(Human_DGE) 
my_cpm<-cpm(y) 
my_cpm[is.na(my_cpm)]<-0 
keep <- rowSums(my_cpm>1) >= 5 
sum(keep) 
y<-y[keep,] 
dim(y) 
y$samples$lib.size<-colSums(y$counts) 
my_cpm<-cpm(y) 
my_cpm[is.na(my_cpm)]<-0 
corner(my_cpm) 
seur_cpm<-new('seurat', raw.data=as.data.frame(log(my_cpm+1))) 
seur_cpm<-setup(seur_cpm, project="MouseSarc_Human", names.field=1, names.delim="_", min.cells=2, 
min.genes=500, is.expr=1) 
seur_cpm 
seur_cpm=mean.var.plot(seur_cpm, y.cutoff=2, x.low.cutoff=2,fxn.x=expMean, fxn.y=logVarDivMean) 
seur_cpm<-pca(seur_cpm, do.print=FALSE) 
viz.pca(seur_cpm, 1:4) 
seur_cpm <- jackStraw(seur_cpm, num.replicate=200, do.print=FALSE) 
jackStrawPlot(seur_cpm, PCs=1:18) 
``` 
 
Pick the only the most significant PCs. 
```{r} 
pc_use<-c(1:3, 5, 8, 10) 
seur_cpm<-run_tsne(seur_cpm, dims.use=pc_use, max_iter=2000) 
tsne.plot(seur_cpm, pt.size=3) 
seur_cpm@var.genes 
#doHeatMap(seur_cpm,genes.use = seur_cpm@var.genes,slim.col.label = TRUE,remove.key = 
TRUE,cexRow=0.1) 
seur_cpm <- DBclust_dimension(seur_cpm, 1, 2, reduction.use="tsne", G.use=8, set.ident=TRUE) 
tsne.plot(seur_cpm, do.label=TRUE, label.pt.size=0.8) 
 
markers.all <- find_all_markers(seur_cpm ,thresh.test = 3,test.use = "roc", do.print = TRUE) 
write.table(markers.all, file="/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-Seq/DS14-
MouseSarc/DS14_Human_gene-markers.txt", quote=F) 
``` 
 
Add in the original Osteosarcoma data from DS3: 
```{r} 
DS3_Data<-read.table("/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-
Seq/DS3_DS4_Oct_2015_Osteosarc_UCH1/BioPolymers_Jan_07_2015/DS3_Osteo_Seq1_Summed-
Seq2-Seq3_DGE.txt", header=T, row.names=1) 
 
colnames(Human_DGE)<-paste("DS14-Seq1-",colnames(Human_DGE), sep="") 
 
all_data<-merge(Human_DGE, DS3_Data, by=0, all=T) 
dim(all_data) 
all_data[is.na(all_data)]<-0 
rownames(all_data)<-all_data[,1] 
all_data<-all_data[,2:length(colnames(all_data))] 
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write.table(all_data, file="/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-Seq/DS14-
MouseSarc/DS14_DS3_Merged_DGE.txt", quote=F) 
 
y<-DGEList(all_data) 
my_cpm<-cpm(y) 
my_cpm[is.na(my_cpm)]<-0 
keep <- rowSums(my_cpm>1) >= 5 
sum(keep) 
y<-y[keep,] 
dim(y) 
y$samples$lib.size<-colSums(y$counts) 
my_cpm<-cpm(y) 
my_cpm[is.na(my_cpm)]<-0 
corner(my_cpm) 
seur_cpm<-new('seurat', raw.data=as.data.frame(log(my_cpm+1))) 
seur_cpm<-setup(seur_cpm, project="DS3_DS14_Osteosarc_Xenograft", names.field=1, 
names.delim="_", min.cells=2, min.genes=500, is.expr=1) 
seur_cpm 
seur_cpm=mean.var.plot(seur_cpm, y.cutoff=2, x.low.cutoff=2,fxn.x=expMean, fxn.y=logVarDivMean) 
seur_cpm<-pca(seur_cpm, do.print=FALSE) 
viz.pca(seur_cpm, 1:4) 
seur_cpm <- jackStraw(seur_cpm, num.replicate=200, do.print=FALSE) 
jackStrawPlot(seur_cpm, PCs=1:21) 
``` 
 
Pick the only the significant PCs. 
```{r} 
pc_use<-c(1:9, 12, 13, 19) 
seur_cpm<-run_tsne(seur_cpm, dims.use=pc_use, max_iter=2000) 
tsne.plot(seur_cpm, pt.size=3) 
seur_cpm@var.genes 
feature.plot(seur_cpm, c("P4HA1", "P4HA2", "P4HB", "P4HTM")) 
feature.plot(seur_cpm, c("FAP", "VIM", "S100A4")) 
feature.plot(seur_cpm, c("CD4", "CD14")) 
 
#doHeatMap(seur_cpm,genes.use = seur_cpm@var.genes,slim.col.label = TRUE,remove.key = 
TRUE,cexRow=0.1) 
seur_cpm <- DBclust_dimension(seur_cpm, 1, 2, reduction.use="tsne", G.use=4, set.ident=TRUE) 
tsne.plot(seur_cpm, pt.size=3) 
``` 
 
Can't seem to get a good grouping through clustering. See if I can find differentially expressed genes 
between new xenograft data and original tumor cells: 
```{r} 
seur_cpm <- set.all.ident(seur_cpm, "orig.ident") 
DS14_markers<-find.markers(seur_cpm, "DS14-Seq1-Optiprep", thresh.use=2) 
DS14_markers_roc<-find.markers(seur_cpm, "DS14-Seq1-Optiprep", thresh.use=2, test.use="roc") 
 
write.table(DS14_markers, file="/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-Seq/DS14-
MouseSarc/DS14_DS3_diff_exp_bimod.txt", quote=F) 
write.table(DS14_markers_roc, file="/Users/Stefan/Documents/CCIB_Work/Single_Cell/Drop-Seq/DS14-
MouseSarc/DS14_DS3_diff_exp_roc.txt", quote=F) 
```
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APPENDIX IV – Script to Control Dolomite Pumps 
//This script is based on a script provided by Patrick from Dolomite. 
//Significant modifications have been made by Stefan Halvorsen from CCIB 
 
using System; 
using Blacktrace.HardwareDefinition; 
using FlowControlCenter.Model; 
using FlowControlCenter.Scripting; 
 
public class MyScript : Script 
{ 
    public override Version GetApiVersion() 
    { 
        return new Version(1,0,0,0); 
    } 
     
    protected override void OnLoad() 
    {  
        // Short description of what this script is for 
        DefineDescription("RNA-Seq FCC protocol."); 
 
        // The following line defines a help file, for example, a pdf describing 
        // this protocol in detail. 
        DefineHelpFile("RNA_Seq help file.pdf"); //this doesn't exist yet 
                           
        // The following line defines devices to be used by this script. 
        // Defining the P pumps and flow sensors - "false" is for no initial target. 
        DefineApparatus("Oil pump", DeviceClass.PressurePump, false); 
        DefineApparatus("Cells pump", DeviceClass.PressurePump, false); 
        DefineApparatus("Beads pump", DeviceClass.PressurePump, false); 
         
        //define flow rates 
        //DefineNumericParam("Priming flow rate", min, max, default,Unit.MicrolitrePerMinute,0); 
        //DefineAdvancedNumericParam("Priming flow rate", 6, 300, 50,Unit.MicrolitrePerMinute,0); // 
"Advanced" ones are default hidden 
        DefineNumericParam("Cells droplet flow rate", 1, 50, 30,Unit.MicrolitrePerMinute,0); 
        DefineNumericParam("Beads droplet flow rate", 1, 50, 30,Unit.MicrolitrePerMinute,0); 
        DefineNumericParam("Oil droplet flow rate", 1, 1000, 166,Unit.MicrolitrePerMinute,0); 
         
         
        DefineAdvancedNumericParam("Bead Priming Compensation", 0, 2, 0.96, Unit.None, 2); 
         
        //define sample volume 
        DefineNumericParam("Aqueous Sample Volume to Run", 100, 2000, 980, Unit.Microlitre, 0); 
         
        DefineAdvancedNumericParam("Ramp Steps", 1, 100, 7, Unit.None, 0); 
        DefineAdvancedNumericParam("Time Between Steps", 0, 100, 7, Unit.Second, 0); 
         
        //define pressures 
        DefineAdvancedNumericParam("Priming pressure", 0, 6000, 300,Unit.Millibar,0); 
        DefineNumericParam("Cells droplet pressure", 0, 5000, 1000,Unit.Millibar,0); 
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        DefineNumericParam("Beads droplet pressure", 0, 5000, 1000,Unit.Millibar,0); //higher because of 
sample loop and viscous Ficoll 
        DefineNumericParam("Oil droplet pressure", 0, 5000, 1600,Unit.Millibar,0); 
        DefineAdvancedNumericParam("Cleaning pressure", 0, 9000, 5000,Unit.Millibar,0); 
         
        //Define Priming Mode 
        DefineAdvancedNumericParam("Priming Flow Control", 0, 1, 0, Unit.None, 0); 
     
        //define 'methods', which are 'sub routines' in the FCC protocols 
        DefineMethod("All", "Prime tubing, run sample, and clean"); 
        DefineMethod("Prime", "Only prime the tubing"); 
        DefineMethod("Run", "Process sample"); 
        DefineMethod("Clean system", "Clean system if finished for the day"); 
     
        Image = "Microfluidics_Chip.JPG"; //not all of these images are there, yet     
    } 
 
 
    protected override void OnTimerTick() 
    { 
//         string[] pumps = new string[] {"Oil pump", "Cells pump", "Beads pump"}; 
//         foreach (string pump in pumps) 
//         { 
//             if (Apparatus[pump].TargetFlowRate != 0) 
//             { 
//                 if ((Math.Abs(Apparatus[pump].CurrentFlowRate - 
Apparatus[pump].TargetFlowRate)/Apparatus[pump].TargetFlowRate) > 0.1) 
//                 { 
//                     var target = Apparatus[pump].TargetFlowRate; 
//                     Output += "Toggle"; 
//                     Apparatus[pump].Stop(); 
//                     Apparatus[pump].TargetFlowRate = target; 
//                     //Apparatus[pump].TargetPressure = Apparatus[pump].CurrentPressure; 
//                     //Apparatus[pump].TargetFlowRate = target; 
//                 } 
//             } 
//         } 
        string submethod = "Init"; 
        int Prime_start = 1; 
        int Prime_end = 5; 
        int Run_start = 6; 
        int Run_end = 10; 
        int Clean_start = 11; 
        int Clean_end = 15; 
         
        if ((Step.Number >= Prime_start)  && (Step.Number <= Prime_end)) submethod = "Prime"; 
        else if ((Step.Number >= Run_start) && (Step.Number <= Run_end)) submethod = "Run"; 
        else if ((Step.Number >= Clean_start) && (Step.Number <= Clean_end)) submethod = "Clean"; 
        else if (Step.Number > Clean_end) submethod = "Finished"; 
         
         
        switch (Method) 
        { 
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            case "Prime": 
            if (submethod == "Init") Step.JumpTo(Prime_start); 
            else if (submethod != "Prime") Finish(); 
            break; 
         
            case "All": 
            if (submethod == "Init") Step.JumpTo(Prime_start); 
            else if (submethod == "Finished") Finish(); 
            break; 
         
            case "Run": 
            if (Step.Number < Run_start) Step.JumpTo(Run_start); 
            else if (Step.Number > Run_end) Finish(); 
            break; 
 
            case "Clean system": 
            if (Step.Number < Clean_start) Step.JumpTo(Clean_start); 
            if (Step.Number > Clean_end) Finish(); 
            break; 
         
            default: 
            break; 
        } 
         
        switch (Step.Number) 
        { 
            //##################### PRIMING ##################### 
            case 1: 
            if (!Step.IsInitialized) 
                { 
                    Output += "Step " + Step.Number + "; waiting for loading..."; 
                    Status="Step " + Step.Number + "; Load emulsion oil into emulsion oil pump, cells into cells 
pump, beads into beads pump, " +  
                    "but don't connect the connector to the chip yet." + "\n\nWhen pumps are loaded, press 
[Resume]"; 
                    Apparatus["Oil pump"] .TargetPressure = 0; 
                    Apparatus["Beads pump"].TargetPressure = 0; 
                    Apparatus["Cells pump"].TargetPressure = 0; 
                    ResumeButton.Text = "Resume"; 
                    ResumeButton.ToolTip = "Carry on by pressing this button"; 
                    Pause(); 
                    Step.IsInitialized=true; 
                } 
            Step.Next(); 
            break; 
             
            case 2: 
            // priming oil tubing up to multiflux connector 
            if (!Step.IsInitialized) 
            { 
                Output += "Step " + Step.Number + ":  priming Oil tubing with " + Apparatus["Oil pump"].Label 
+ "...";  
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                Status="Step " + Step.Number + "priming tubing with emulsion oil from the oil pump \u0022" + 
Apparatus["Oil pump"].Label + "\u0022;" + //unicode for ": \u0022 
                "\n\nWhen the tubing is full and a droplet appears at connector, press [Resume] ";     
                Image = "connector droplet.jpg";  
                Apparatus["Oil pump"].TargetPressure = Parameters["Priming pressure"]; 
                SkipButton.Text = " "; //clear skip button text 
                SkipButton.ToolTip = " "; 
                Pause(); 
                ResumeButton.Text = "Resume"; 
                ResumeButton.ToolTip = "Press this button when oil droplet appears at connector"; 
                Step.IsInitialized=true;     
            } 
            Step.Next(); 
            break; 
             
            case 3: 
            //  priming beads tubing 
            if (!Step.IsInitialized) 
            { 
                Output+="Step " + Step.Number + "; priming tubing from Reagent pump 2..";     
                Status="Step " + Step.Number + "priming tubing with fluid from Beads pump \u0022" + 
Apparatus["Beads pump"].Label + "\u0022;" +  
                "\n\nWhen the tubing is full and a droplet appears at the connector, press [Resume] ";     
                Image = "Injection valve.jpg"; 
                Apparatus["Oil pump"].TargetPressure=0; 
                Apparatus["Beads pump"].TargetPressure = Parameters["Priming pressure"]; 
                Pause(); 
                ResumeButton.Text = "Resume"; 
                ResumeButton.ToolTip = "Press this button when droplet appears at injection valve"; 
                Step.IsInitialized=true; 
            } 
            Step.Next(); 
            break; 
             
            case 4: 
            // priming cells tubing up to multiflux connector 
            if (!Step.IsInitialized) 
            { 
                Output+="Step " + Step.Number + "; priming tubing from Reagent pump 1.."; 
                Status="Step " + Step.Number + "priming tubing with cells from Cells pump, \u0022" + 
Apparatus["Cells pump"].Label + "\u0022;" +  
                "\n\nWhen the tubing is full and a droplet appears at connector, press [Resume] ";     
                Image = "connector droplet.jpg";  
                Apparatus["Oil pump"].TargetPressure=0; 
                Apparatus["Beads pump"].TargetPressure=0; 
                Apparatus["Cells pump"].TargetPressure = Parameters["Priming pressure"]; 
                Pause(); 
                ResumeButton.Text = "Resume"; 
                ResumeButton.ToolTip = "Press this button when cell suspension droplet appears at connector"; 
                Step.IsInitialized=true; 
            } 
            Step.Next(); 
            break; 
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            case 5: 
            //  prompt user to connect the connector to the chip 
            if (!Step.IsInitialized) 
            { 
                Apparatus["Oil pump"].TargetPressure=0; 
                Apparatus["Beads pump"].TargetPressure=0; 
                Apparatus["Cells pump"].TargetPressure=0; 
                Output+="Step " + Step.Number + "; connect the chip"; 
                Status="Step " + Step.Number + "; your system should now be ready to process the sample. \n\n" 
+  
                "To automatically process your sample into droplets, connect the connector to the chip, connect 
the output tubing to the " + 
                "output reservoir, and press [Resume]"; 
                //image = "connecting connector.jpg";  
                Pause(); 
                ResumeButton.Text = "Resume"; 
                ResumeButton.ToolTip = "Process your sample by pressing this button"; 
                SkipButton.Text = ""; 
                SkipButton.ToolTip = ""; 
            }     
            Step.Next(); 
            break; 
             
            //##################### RUNNING ##################### 
            case 6: 
            //  pumps on, priming chip 
            if (!Step.IsInitialized) 
            { 
                Output+="Step " + Step.Number + ": processing sample"; 
                Step.IsInitialized=true; 
                ResumeButton.Text = ""; 
                ResumeButton.ToolTip = ""; 
            } 
            double Step_No = Step.ElapsedSeconds / Parameters["Time Between Steps"]; 
            Step_No = Math.Truncate(Step_No); 
            if (Parameters["Priming Flow Control"] == 1) 
            { 
                var oil_priming_flow = Math.Min( 
                    (Parameters["Oil droplet flow rate"]/Parameters["Ramp Steps"] * Step_No) 
                    , Parameters["Oil droplet flow rate"]); 
                var cells_priming_flow = Math.Min( 
                    ((Parameters["Cells droplet flow rate"])/Parameters["Ramp Steps"] * Step_No) 
                    , (Parameters["Cells droplet flow rate"])); 
                //Set beads slightly lower to prevent possibility of backflow and getting lysis buffer in cells line 
                var beads_priming_flow = Math.Min( 
                    ((Parameters["Beads droplet flow rate"])/Parameters["Ramp Steps"] * Step_No * 
Parameters["Bead Priming Compensation"]) 
                    , (Parameters["Beads droplet flow rate"])); 
                // the pressures are trimmed to within allowed pressures to avoid erroring out 
                // trim function found here: 
                // private double TrimTargetFlow(double desiredTargetPressure, string pumpLabel) 
                var num_pumps = 3; 
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                var pump_run = Step.ElapsedSeconds % num_pumps; 
                //For some reason, setting all the pumps at the same time causes some pumps not to respond. Set 
them separately, and toggle the pressure/flow control modes to help reliability. I don't know why this helps. 
                if (pump_run == 0) 
                { 
                    //For some reason, toggling the pressure/flow control mode on the same pump right after one 
another causes the flow control values to go haywire 
                    Apparatus["Cells pump"].TargetFlowRate=TrimTargetFlow(cells_priming_flow, "Cells 
pump"); 
                    Apparatus["Beads pump"].TargetPressure = TrimTargetPressure(Apparatus["Beads 
pump"].ChamberPressure, "Beads pump"); 
                } 
                else if (pump_run == 1) 
                { 
                    Apparatus["Oil pump"].TargetFlowRate = TrimTargetFlow(oil_priming_flow, "Oil pump"); 
                    Apparatus["Cells pump"].TargetPressure = TrimTargetPressure(Apparatus["Cells 
pump"].ChamberPressure, "Cells pump"); 
                } 
                else if (pump_run == 2) 
                { 
                    Apparatus["Beads pump"].TargetPressure = TrimTargetPressure(Apparatus["Beads 
pump"].ChamberPressure, "Beads pump"); 
                    Apparatus["Oil pump"].TargetPressure = TrimTargetPressure(Apparatus["Oil 
pump"].ChamberPressure, "Oil pump"); 
                } 
            } 
            else 
            { 
                var oil_priming_pressure = Math.Min( 
                    (Parameters["Oil droplet pressure"]/Parameters["Ramp Steps"] * Step_No) 
                    , Parameters["Oil droplet pressure"]); 
                var cells_priming_pressure = Math.Min( 
                    ((Parameters["Cells droplet pressure"])/Parameters["Ramp Steps"] * Step_No) 
                    , (Parameters["Cells droplet pressure"])); 
                //Set beads slightly lower to prevent possibility of backflow and getting lysis buffer in cells line 
                var beads_priming_pressure = Math.Min( 
                    ((Parameters["Beads droplet pressure"])/Parameters["Ramp Steps"] * Step_No * 
Parameters["Bead Priming Compensation"]) 
                    , (Parameters["Beads droplet pressure"])); 
                // the pressures are trimmed to within allowed pressures to avoid erroring out 
                // trim function found here: 
                // private double TrimTargetFlow(double desiredTargetPressure, string pumpLabel) 
                Apparatus["Oil pump"].TargetPressure = TrimTargetPressure(oil_priming_pressure, "Oil 
pump"); 
                Apparatus["Cells pump"].TargetPressure=TrimTargetPressure(cells_priming_pressure, "Cells 
pump"); 
                Apparatus["Beads pump"].TargetPressure=TrimTargetPressure(beads_priming_pressure, "Beads 
pump"); 
            } 
            Status="Step " + Step.Number + ". Priming chip."; 
            //if we are up to the flow rates continue to collection 
            if (Step.ElapsedSeconds >= Parameters["Ramp Steps"]*Parameters["Time Between Steps"]) 
            { 
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                Step.Next(); 
            } 
            break; 
             
            case 7: 
            // collecting droplets 
            double runtime = Parameters["Aqueous Sample Volume to Run"] / Math.Min(Parameters["Cells 
droplet flow rate"], Parameters["Beads droplet flow rate"]) * 60; 
            if (!Step.IsInitialized) 
            { 
                Output+="Step " + Step.Number + ": collecting to collection vessel"; 
                SkipButton.Text = "Move On"; 
                SkipButton.ToolTip = "Press this button to complete"; 
                SkipButton.OnClick = delegate { Step.Next(); }; 
                Step.IsInitialized=true; 
            } 
            //switch to flow control for any of the pumps that have flow sensors 
            if (Apparatus["Oil pump"].FlowSensorType==0) // FlowSensorType==0 i.e. no flow sensor present 
                {Apparatus["Oil pump"] .TargetPressure = Parameters["Oil droplet pressure"];} 
            else  
                {Apparatus["Oil pump"].TargetFlowRate = Parameters["Oil droplet flow rate"];} 
         
            if (Apparatus["Beads pump"].FlowSensorType==0)  
                {Apparatus["Beads pump"] .TargetPressure = Parameters["Beads droplet pressure"];} 
            else  
                {Apparatus["Beads pump"].TargetFlowRate = Parameters["Beads droplet flow rate"];} 
     
                if (Apparatus["Cells pump"].FlowSensorType==0)  
                {Apparatus["Cells pump"] .TargetPressure = Parameters["Cells droplet pressure"];} 
            else  
                {Apparatus["Cells pump"].TargetFlowRate = Parameters["Cells droplet flow rate"];} 
            //countdown timer 
            Status = "Step " + Step.Number + "; processing sample. When the collection is complete, the pumps 
will stop. \n\n" +  
            string.Format("Time remaining in this step: {0:c}", TimeSpan.FromSeconds(runtime) - 
Step.ElapsedTime); 
            if (Step.ElapsedTime >= TimeSpan.FromSeconds(runtime)) 
            { 
                Step.Next();  
            } 
            break; 
             
            case 8: 
            if (!Step.IsInitialized) 
            { 
                Output+="Step " + Step.Number + ": finished collecting droplets, pumps stopping"; 
                SkipButton.Text = "Move On"; 
                SkipButton.ToolTip = "Press this button to complete"; 
                SkipButton.OnClick = delegate { Step.Next(); }; 
                Step.IsInitialized=true; 
            } 
            Step_No = Step.ElapsedSeconds / Parameters["Time Between Steps"]; 
            Step_No = Math.Truncate(Step_No); 
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            if (Parameters["Priming Flow Control"] == 1) 
            { 
                var Cells_ramp_down = Math.Max( 
                    (Parameters["Cells droplet flow rate"]  
                    - (Parameters["Cells droplet flow rate"] / Parameters["Ramp Steps"])* Step_No) 
                    , 0); 
                //Set beads slightly lower to prevent possibility of backflow and getting lysis buffer in cells line 
                var Beads_ramp_down = Math.Max( 
                    (Parameters["Beads droplet flow rate"]  
                    - (Parameters["Beads droplet flow rate"] / Parameters["Ramp Steps"])* 
Step_No)*Parameters["Bead Priming Compensation"] 
                    , 0); 
                var Oil_ramp_down = Math.Max( 
                    (Parameters["Oil droplet flow rate"]  
                    - (Parameters["Oil droplet flow rate"] / Parameters["Ramp Steps"])* Step_No) 
                    , 0); 
                var num_pumps = 3; 
                var pump_run = Step.ElapsedSeconds % num_pumps; 
                if (pump_run == 0) 
                { 
                    Apparatus["Cells pump"].TargetPressure = TrimTargetPressure(Apparatus["Cells 
pump"].ChamberPressure, "Cells pump"); 
                    Apparatus["Cells pump"].TargetFlowRate=TrimTargetFlow(Cells_ramp_down, "Cells 
pump"); 
                } 
                if (pump_run == 1) 
                { 
                    Apparatus["Beads pump"].TargetPressure = TrimTargetPressure(Apparatus["Beads 
pump"].ChamberPressure, "Beads pump"); 
                    Apparatus["Beads pump"].TargetFlowRate=TrimTargetFlow(Beads_ramp_down, "Beads 
pump"); 
                } 
                if (pump_run == 2) 
                { 
                    Apparatus["Oil pump"].TargetPressure = TrimTargetPressure(Apparatus["Oil 
pump"].ChamberPressure, "Oil pump"); 
                    Apparatus["Oil pump"].TargetFlowRate = TrimTargetFlow(Oil_ramp_down, "Oil pump"); 
                } 
            } 
            else 
            { 
                var Cells_ramp_down = Math.Max( 
                    (Parameters["Cells droplet pressure"]  
                    - (Parameters["Cells droplet pressure"] / Parameters["Ramp Steps"])* Step_No) 
                    , 0); 
                //Set beads slightly lower to prevent possibility of backflow and getting lysis buffer in cells line 
                var Beads_ramp_down = Math.Max( 
                    (Parameters["Beads droplet pressure"]  
                    - (Parameters["Beads droplet pressure"] / Parameters["Ramp Steps"])* 
Step_No)*Parameters["Bead Priming Compensation"] 
                    , 0); 
                var Oil_ramp_down = Math.Max( 
                    (Parameters["Oil droplet pressure"]  
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                    - (Parameters["Oil droplet pressure"] / Parameters["Ramp Steps"])* Step_No) 
                    , 0); 
                Apparatus["Oil pump"].TargetPressure = TrimTargetPressure(Oil_ramp_down, "Oil pump"); 
                Apparatus["Cells pump"].TargetPressure=TrimTargetPressure(Cells_ramp_down, "Cells pump"); 
                Apparatus["Beads pump"].TargetPressure=TrimTargetPressure(Beads_ramp_down, "Beads 
pump"); 
            } 
            Status="Step " + Step.Number + "; finished collecting droplets, stopping pumps."; 
            if (Step.ElapsedSeconds >= Parameters["Ramp Steps"]*Parameters["Time Between Steps"]) 
            { 
                //For some reason, software seems to change to pressure control mode when setting target to 0, 
                //but does not execute pressure change to 0 some times. 
                //Put the change here, and repeat the request for 0 pressure in next step. 
                Apparatus["Oil pump"] .TargetPressure = 0; 
                Apparatus["Cells pump"].TargetPressure = 0; 
                Apparatus["Beads pump"].TargetPressure = 0; 
                Step.Next(); 
            } 
            break; 
             
            case 9: 
            Step.Next(); 
            break; 
             
            case 10: 
            //  stop pumps, pause until user removes processed emulsion, and connects outlet to waste     
            if (!Step.IsInitialized) 
            { 
                Status="Step " + Step.Number + "; sample has been processed into droplets. \n\n" + 
                "Disconnect outlet tubing from droplet collection reservoir, remove processed sample, press 
[Resume]."; 
                Output+="Step " + Step.Number + ": finished collecting droplets, pumps stopped"; 
                Apparatus["Oil pump"] .TargetPressure = 0; 
                Apparatus["Cells pump"].TargetPressure = 0; 
                Apparatus["Beads pump"].TargetPressure = 0; 
                SkipButton.Text = " "; //clear skip button text 
                SkipButton.ToolTip = " "; 
                Pause(); 
                ResumeButton.Text = "Resume"; 
                ResumeButton.ToolTip = "Carry on by pressing this button"; 
                //Image = "image.jpg";  
            }     
            Step.Next(); 
            break; 
             
            //##################### CLEANING ##################### 
            case 11: 
            //  prepare for system clean and shutdown 
            if (!Step.IsInitialized) 
            { 
                Output+= "Step " + Step.Number + ": prepare for system clean and shutdown"; 
                Status="Step " + Step.Number + ": preparing to clean system and shut down. " + 
                "Remove fluid reservoirs (including emulsion oil) from all P-Pump reservoirs " + 
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                "and replace with vials containing 0.5 ml of filtered 1% SDS. Connect connector to chip " + 
                "and output tubing to waste.\n\n" + 
                "To flush the system with detergent and air, press [Resume]"; 
                // set all pumps to 0 at beginning of 'method' 'sub routine' just in case 
                Apparatus["Oil pump"] .TargetPressure = 0; 
                Apparatus["Cells pump"].TargetPressure = 0; 
                Apparatus["Beads pump"].TargetPressure = 0; 
                SkipButton.Text = " "; //clear skip button text 
                SkipButton.ToolTip = " "; 
                Pause(); 
                ResumeButton.Text = "Resume"; 
                ResumeButton.ToolTip = "Carry on by pressing this button"; 
                Step.IsInitialized=true; 
            } 
            Step.Next(); 
            break; 
             
            case 12: 
            //  Flush system with detergent and air 
            if (!Step.IsInitialized) 
            { 
                Output+="Step " + Step.Number + ": Flush with detergent and air for 10 minutes"; 
                Apparatus["Oil pump"] .TargetPressure = Parameters["Cleaning pressure"]; 
                Apparatus["Beads pump"].TargetPressure = Parameters["Cleaning pressure"]; 
                Apparatus["Cells pump"].TargetPressure = Parameters["Cleaning pressure"]; 
                Step.IsInitialized=true; 
                SkipButton.Text = "Next"; 
                SkipButton.ToolTip = "Press this button to move to next step"; 
                SkipButton.OnClick = delegate { Step.Next(); }; 
            } 
            if (Step.ElapsedTime.GreaterThanOrEqual(0,10,0)) Step.Next(); //reduce this time to something 
sensible when you try it out 
            Status="Step " + Step.Number + "; flushing with air. \n\n" +  
            string.Format("Time remaining in this step: {0:c}", TimeSpan.FromSeconds(602) - 
Step.ElapsedTime); 
            break; 
             
            case 13: 
            //  prepare to flush cells line with isopropanol and air 
            if (!Step.IsInitialized) 
            { 
                Output+= "Step " + Step.Number + ": prepare to flush cells line with isopropanol and air"; 
                Status="Step " + Step.Number + ": preparing to flush system with isopropanol and air. " + 
                "Remove detergent microcentrifuge tubes from all P-Pump reservoirs " + 
                "and replace with vials containing 0.5 ml of filtered isopropanol.\n\n" + 
                "To flush the system with isopropanol and air, press [Resume]"; 
                Apparatus["Oil pump"] .TargetPressure = 0; 
                Apparatus["Beads pump"].TargetPressure = 0; 
                Apparatus["Cells pump"].TargetPressure = 0; 
                Pause(); 
                ResumeButton.Text = "Resume"; 
                ResumeButton.ToolTip = "Carry on by pressing this button"; 
                Step.IsInitialized=true; 
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            } 
            Step.Next(); 
            break; 
             
            case 14: 
            //  Flush cells line with isopropanol and air. The intention is that the flush time is long enough that  
            // the buffer is used up, there will consequently be a final air flush 
            if (!Step.IsInitialized) 
            { 
                Output+= "Step " + Step.Number + ":Flush cells line with isopropanol and air"; 
                Apparatus["Oil pump"] .TargetPressure = Parameters["Cleaning pressure"]; 
                Apparatus["Beads pump"].TargetPressure = Parameters["Cleaning pressure"]; 
                Apparatus["Cells pump"].TargetPressure = Parameters["Cleaning pressure"]; 
                Step.IsInitialized=true; 
                SkipButton.Text = "Next"; 
                SkipButton.ToolTip = "Press this button to move to next step"; 
                SkipButton.OnClick = delegate { Step.Next(); }; 
            } 
            if (Step.ElapsedTime.GreaterThanOrEqual(0,10,0)) Step.Next(); //reduce this time to something 
sensible when you try it out 
            Status="Step " + Step.Number + "; flushing with isopropanol and air. \n\n" +  
            string.Format("Time remaining in this step: {0:c}", TimeSpan.FromSeconds(602) - 
Step.ElapsedTime); 
            break; 
             
            case 15: 
            //  complete!     
            Output+="Step " + Step.Number + ": complete!"; 
            Status="Step " + Step.Number + "; Complete! \n\n" + 
            "Remove microcentrifuge tubes from P-Pump reservoirs, and shut down.";  
                Apparatus["Oil pump"] .TargetPressure = 0; 
                Apparatus["Beads pump"].TargetPressure = 0; 
                Apparatus["Cells pump"].TargetPressure = 0; 
            Status = "CONGRATULATIONS!! This is only the beginning..."; 
            Image = "Thumbs_Up.jpg"; 
            Step.Next(); 
            break; 
             
            default: 
            break; 
        } 
    } 
     
    private double TrimTargetPressure(double desiredTargetPressure, string pumpLabel) 
    { 
        // Check lower limit 
        double target = Math.Max(Apparatus[pumpLabel].MinTargetPressure, desiredTargetPressure); 
        // Check upper limit 
        return Math.Min(target, Apparatus[pumpLabel].MaxTargetPressure); 
    } 
     
    private double TrimTargetFlow(double desiredTargetFlow, string pumpLabel) 
    { 
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        /*// Check lower limit 
        double target = Math.Max(Apparatus[pumpLabel].MinTargetFlowRate, desiredTargetFlow); 
        // Check upper limit 
        return Math.Min(target, Apparatus[pumpLabel].MaxTargetFlowRate); 
        */ 
        //Min and Max FlowRates don't seem to be recorded correctly. For now, just return the input value. 
        return desiredTargetFlow; 
    } 
     
    protected override void CheckForError() 
    { 
        if ( (Apparatus["Oil pump"].MaxTargetPressure < Apparatus["Oil pump"].TargetPressure) || 
(Apparatus["Cells pump"].MaxTargetPressure < Apparatus["Cells pump"].TargetPressure) || 
(Apparatus["Beads pump"].MaxTargetPressure <Apparatus["Beads pump"].TargetPressure)  ) 
        {     
            Output+="Supply pressure has dropped too low for one or more pumps - please increase supply 
pressure before continuing"; 
            Pause(); 
        } 
        // Call the default implementation to check if any device reported an error so we still stop the script on 
fatal hardware errors: 
        base.CheckForError(); 
    } 
     
}  
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APPENDIX V – Primer Sequences 
Template Swith Oligo: AAGCAGTGGTATCAACGCAGAGTGAATrGrGrG	
PCR Primer: 
AAGCAGTGGTATCAACGCAGAGT 
P5 Primer: 
AATGATACGGCGACCACCGAGATCTACACGCCTGTCCGCGGAAGCAGTGGTA
TCAACGCAGAGT*A*C 
 
P7 Oligo – N701: 
CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTCTCGTGGGCTCGG 
P7 Oligo – N702: 
CAAGCAGAAGACGGCATACGAGATCTAGTACGGTCTCGTGGGCTCGG 
P7 Oligo – N703: 
CAAGCAGAAGACGGCATACGAGATTTCTGCCTGTCTCGTGGGCTCGG 
Custom read1 Primer: 
GCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGTACGT 
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